

	著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	保坂哲也	B 型慢性肝炎、肝硬変： 抗ウイルス療法	福井次矢 高木誠 小室一成	今日の治療 指針	医学書院	東京	2022	540-543	
2)	保坂哲也	B 型慢性肝疾患における 機械学習を用いた肝線維 化予測	中本安成	雑誌肝胆膵 1 月号	アークメ ディア	東京	2022	47-50	○
3)	保坂哲也	臨床疫学からみた肝炎と の闘い（B 型慢性肝炎の 自然史と抗ウイルス療法 の発展）	田中純子	雑誌メディ カル・サイ エンスダイ ジェスト 12 月号	ニューサ イエンス 社	東京	2021	18-21	○
4)	保坂哲也 鈴木義之	B 型慢性肝炎の治療、3 核 酸アナログ	三田英治 平松直樹	必ず役立 つ！肝炎診 療バイブル	メディカ 出版	大阪	2021	126-135	○
5)	佐竹正博	輸血後肝炎の撲滅に向け て	田中純子	Medical Science Digest	ニューサ イエンス 社	東京	2021	10-13	○
6)	瀬戸山博子、島上 哲朗、考藤達哉	日本における肝炎総合対 策	田中純子	Medical Science Digest	ニューサ イエンス 社	東京都 目黒区	2021	No.14, 716-719	○
7)	川口巧、鳥村拓司	第 2 章 栄養療法の基礎 II. 栄養評価 E. 窒素代謝 および窒素平衡	一般社団法人 日本臨床 栄養代謝学 会	日本臨床栄 養代謝学会 JSPEN テキ ストブック	南江堂	東京	2021	164-168	
8)	鳥村拓司	腸内細菌と肝細胞癌	木下芳一、 他 編	専門医のため の消化器 病学	医学書院	東京	2021	444-446	
9)	川口巧、鳥村拓司	代謝異常と中等度飲酒が 脂肪肝患者の肝線維化に およぼす影響	アルコール 医学生物学 研究会 編	アルコール と医学生物 学 Vol. 40	梵天書房	東京	2021	45-46	
10)	相崎英樹	C 型肝炎ウイルスの感染 増殖と病原性発現メカニ ズム、創薬研究者がこれ だけは知っておきたい最 新のウイルス学	技術情報協 会	技術情報協 会	技術情報 協会	東京	2021	3-11	
11)	青柳東代、村松正 道、脇田隆字、相 崎英樹	C 型肝炎のウイルス学と病 態		C 型肝炎患 者の今後の課 題—肝炎、 肝硬変、肝 がん—	消化器内 科	東京	2021	6-13	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Matsugu Y, Ito K, Oshita A, Nobuhara H, <u>Tanaka J</u> , Akita T, Itamoto T	Postoperative oral energy and protein intakes for an enhanced recovery after surgery program incorporating early enteral nutrition for pancreaticoduodenectomy: A retrospective study	Nutrition in Clinical Practice			in press	
2)	Hayes NC, Imamura M, <u>Tanaka J</u> , Chayama K	Road to elimination of HCV: Clinical challenges in HCV management	Liver International			in press	
3)	Toyoda H, Yasuda S, Shiota S, Kumada T, <u>Tanaka J</u>	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response	European Journal of Gastroenterology and Hepatology			in press	○
4)	Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <u>Tanaka J</u>	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection	European Radiology			in press	○
5)	Manry J, Bastard P, Gervais A, et al, (<u>Tanaka J</u> 含む 180 人中 38 番目)	The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies	Research square			in press	
6)	<u>Tanaka J</u> , Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, Wang ML, Hiebert L, Kanto T, Akita T	Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study	The Lancet regional health. Western Pacific			in press	○
7)	E B, Ou P, Ouoba S, Hussain Md RA, Ko K, Nagashima S, Sugiyama A, Akita T, <u>Tanaka J</u>	Prevalence and genotype distribution of viral hepatitis B in Cambodia between 1990 and 2020: A Systematic Review and Meta-analysis	Archives of Public Health			in press	○
8)	El-Ekiaby M, <u>Tanaka J</u> , van Drimmelen H, Allain JP, Lelie N	Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	Journal of Viral Hepatitis	29(5)	330-339	2022	○
9)	Akita S, Fujioka M, Akita T, <u>Tanaka J</u> , Masunaga A, Kawahara T	Effects of hand hygiene using 4% chlorhexidine gluconate or natural soap during hand rubbing followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion in the operating room	Advances in Wound Care	11(1)	1-9	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
10)	Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshikawa K, Tanaka J , Muramatsu M, Wakita T, Aizaki H	Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	Hepatology International	16(1)	68-80	2022	○
11)	Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	Hepatology Research	52(1)	81-92	2022	○
12)	Ouoba S, Okimoto M, Nagashima S, Kitahara Y, Miwata K, Ko K, E B, Sugiyama A, Takahashi K, Sakaguchi T, Takafuta T, Tanaka J	Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients	Journal of Medical Virology	94(4)	1734-1737	2022	
13)	Imada H, Akita T, Sugiyama A, Tanaka J	Impact of robot-assisted surgery appearance on reduction of annual blood transfusion cases in Japan: application of meta-analysis and NDB open data	Journal of Robotic Surgery	8()	1-4	2022	
14)	Nobuhara H, Matsugu Y, Tanaka J , Akita T, Ito K	The preventive effects of perioperative oral care on surgical site infections after pancreatic cancer surgery: a retrospective study	Support Care Cancer	30(4)	3337-3344	2022	
15)	Blach S, Terrault NA, Tacke F, Gamkrelidze I et al, (Tanaka J 含む 259人中 6 番目)	Global change in hepatitis C virus prevalence as a cascade of care between 2015 and 2020: a modelling study	The LANCET Gastroenterology and Hepatology	7(5)	396-415	2022	○
16)	Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, Omori K, Akita T, Shigemoto N, Tanaka J , Ohge H	Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan	Journal of infection and chemotherapy	28(4)	576-581	2022	
17)	Inoue M, Hirabayashi M, Abe SK, Katanoda K, Sawada N, Lin Y, Ishihara J, Takachi R, Nagata C, Saito E, Goto A, Ueda K, Tanaka J , Hori M, Matsuda T	Burden of cancer attributable to modifiable factors in Japan in 2015	Global health and medicine	4(1)	26-36	2022	○
18)	Ko K, Takahashi K, Nagashima S, E B, Ouoba S, Hussain MRA, Akita T, Sugiyama A, Sakaguchi T, Tahara H, Ohge H, Ohdan H, Kubo T, Ishikawa N, Takafuta T, Fujii Y, Mimori M, Okada F, Kishita E, Ariyoshi K, Kuwabara M, Tanaka J	Mass screening of SARS-CoV-2 variants using sanger sequencing strategy in Hiroshima, Japan	Scientific Reports	12(1)	2419	2022	
19)	Ko K, Takahashi K, Nagashima S, E B, Ouoba S, Takafuta T, Fujii Y, Mimori M, Okada F, Kishita E, Ariyoshi K, Hussain Md RA, Sugiyama A, Akita T, Kuwabara M, Tanaka J	Exercising the Sanger sequencing strategy for variants screening and full-length genome of SARS-CoV-2 virus during alpha, delta, and omicron outbreaks in Hiroshima	Viruses	14(4)	720	2022	
20)	Sugiyama A, Miwata K, Kitahara Y, Okimoto M, Abe K, Ouoba S, Akita T, Tanimine N, Ohdan H, Kubo T, Nagasawa A, Nakanishi T, Takafuta T, Tanaka J	Long COVID occurrence in COVID-19 survivors	Scientific Reports	12(1)	6039	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
21)	Toyoda H, Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Itobayashi E, Watanabe T, Matsuura K, Shimada N, Abe H, Tsuji K, Itokawa N, Mikami S, Ishikawa T, Oikawa T, Yasuda S, Chuma M, <u>Tanaka J</u>	The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C	Gastro Hep Advances	1(4)	508	2022	○
22)	Kaneyasu Y, Fujiwara H, Nishimura T, Sakurai H, Kazumoto T, Ikushima H, Uno T, Tokumaru S, Harima Y, Gomi H, Toita T, Kita M, Noda S, Takahashi T, Kato S, Hirashima Y, Niibe Y, Nakagawa T, Akita T, <u>Tanaka J</u> , Ohno T, the Working Group of the Gynecological Tumor Committee of the Japanese Radiation Oncology Study Group(JROSG)	A multi-institutional survey of the quality of life after treatment for uterine cervical cancer: A comparison between radical radiotherapy and surgery in Japan	Journal of Radiation Research	62(2)	576-585	2021	
23)	Fujimura K, Sugiyama A, Akita T, Ohisa M, Nagashima S, Katayama K, Maeda R, <u>Tanaka J</u>	Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima	International Journal of Hematology	113(4)	538-547	2021	
24)	Ko K, Nagashima S, E B, Ouoba S, Akita T, Sugiyama A, Ohisa M, Sakaguchi T, Tahara H, Ohge H, Ohdan H, Kubo T, Kishita E, Kuwabara M, Takahashi K, <u>Tanaka J</u>	Molecular characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima	PLoS One	16(2)	e0246383	2021	
25)	Toyoda T, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, <u>Tanaka J</u>	Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response	Hepatology Communications	5(7)	1290-1299	2021	○
26)	Kuroda S, Kobayashi T, Tashiro H, Onoe T, Oshita A, Abe T, Kohashi T, Oishi K, Ohmori I, Imaoka Y, <u>Tanaka J</u> , Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology	A multicenter randomized controlled trial comparing administration of antithrombin III after liver resection (HiSCO-05 trial)	Surgery	170(4)		2021	○
27)	Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <u>Tanaka J</u>	Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection	Alimentary Pharmacology and Therapeutics	53(12)		2021	○
28)	Kumada T, Toyoda H, Yasuda S, Sone Y, Ogawa S, Takeshima K, Tada T, Ito T, Sumida Y, <u>Tanaka J</u>	Prediction of hepatocellular carcinoma by liver stiffness measurements using magnetic resonance elastography after eradicating hepatitis C virus	Clinical and translational gastroenterology	12(4)		2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
29)	Kumada T, Toyoda H, Yasuda S, Tada T, Tanaka J , Chayama K, Johnson PJ, Irving WL	Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus	Infectious Diseases and Therapy	10(2)		2021	○
30)	Kumada T, Toyoda H, Yasuda S, Tada T, Tanaka J	Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication	European Journal of Gastroenterology and Hepatology	33		2021	○
31)	Kumada T, Toyoda H, Yasuda S, Tada T, Ito T, Tanaka J	Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis	Journal of Viral Hepatitis	28(9)		2021	○
32)	Sugiyama A, Yamashita M, Ko K, Ohisa M, Akita T, Wakita T, Tanaka J	Epidemiological assessment of interventions to eliminate mother-to-child transmission of hepatitis B virus in Japan	GastroHep	3		2021	○
33)	Maeshige N, Hayashi H, Terashi H, Fujii M, Iwamoto T, Watanabe Yu, Imaoka S, Matsumoto J, Nishikawa M, Takeda N, Mikawa R, Tsuji Y, Higashita R, Ayabe S, Terabe Y, Furukawa M, Tanaka J , Ohura T, Kawabe N	Effect of early rehabilitation on gait, wound and home discharge in lower extremity chronic wound patients: a Japanese multicenter retrospective study	The International Journal of Lower Extremity Wounds		doi:10.1177/15347346211039588	2021	
34)	E B, Ko K, Nagashima S, Ouoba S, Hussain Md RA, Sugiyama A, Akita T, Ohisa M, Chuon C, Mao B, Hossain MS, Ork V, Tanaka J	Dried blood spot-based detection of serological profiles of hepatitis B and C infections and their prevalence in Cambodia	GastroHep	3(4)		2021	○
35)	Toyoda H, Yasuda S, Shiota S, Kumada T, Tanaka J	Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy	Journal of Infection and chemotherapy	27(11)		2021	○
36)	Sugiyama A, Kurisu A, Ouoba S, E B, Ko K, Rakhimov A, Hussain Md RA, Akita T, Harakawa T, Sako T, Koshiyama M, Tanaka J	Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008-2019	Liver International	41(12)		2021	○
37)	Sugimura M, Chimed-Ochir O, Yumiya Y, Ohge H, Shime N, Sakaguchi T, Tanaka J , Takafuta T, Mimori M, Kuwabara M, Asahara T, Kishita E, Kubo T	The Association between Wearing a Mask and COVID-19	International journal of environmental research and public health	18(17)	9131	2021	
38)	Ouoba S, Ouedraogo JCRP, Lingani M, E B, Hussain Md RA, Ko K, Nagashima S, Sugiyama A, Akita T, Tinto H, Tanaka J	Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis	BMC Infectious Disease	21	1126	2021	○

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
39) Sugiyama A, Fujii T, Okikawa Y, Sasaki F, Okajima M, Hidaka H, Iwato K, Sato K, Kokubunji A, Takata N, Yamamoto M, <u>Tanaka J</u>	Outcomes of patients who undergo transfusion of fresh frozen plasma: a prospective, observational, multicentre cohort study in Hiroshima, Japan	Journal of Blood Medicine	12(12)	965-973	2021	
40) Lin Y, Wang C, Kikuchi S, Akita T, <u>Tanaka J</u> , Abe SK, Hirabayashi M, Saito E, Hori M, Katanoda K, Matsuda T, Inoue M, the Cancer PAF Japan Collaborators	Burden of cancer attributable to infection in Japan in 2015	Global Health and Medicine	1(2)	63-69	2021	○
41) Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, <u>Tanaka J</u>	Serial changes in FIB-4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy	GastroHep	3(1)	37-49	2021	○
42) Ko K, Akita T, Satake M, <u>Tanaka J</u>	Epidemiology of viral hepatitis C: Road to elimination in Japan.	Global Health & Medicine	3(5)	262-269	2021	○
43) Kumada T, Toyoda H, Yasuda S, Ito T, <u>Tanaka J</u>	Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B	European Journal of Gastroenterology and Hepatology	33(1S Suppl 1)	e898-e904	2021	○
44) Toyoda H, Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, <u>Tanaka J</u>	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis	Nephrology, dialysis, transplantation	36	1097-1103	2021	○
45) Yoshikawa S, Yoshio S, Yoshida Y, Tsutsui Y, Kawai H, Yamazoe T, Mori T, Osawa Y, Sugiyama M, Iwamoto M, Watashi K, Kawaguchi T, Akita T, <u>Tanaka J</u> , Kikuchi Y, Mizokami M, Oka S, Kanto T, Gatanaga H	Impact of immune reconstitution-induced hepatic flare on HBsAg loss in HBV/HIV-1-coinfected patients	The Journal of Infectious Diseases	223(12)	2080-2089	2021	○
46) Itakura J, Kurosaki M, Setoyama H, Simakami T, Oza N, Korenaga M, Tanaka M, Torimura T, Sakamoto N, Enomoto N, Ueno Y, Kawada N, Kaneko S, Nishiguchi S, Chayama K, <u>Tanaka J</u> , Izumi N, Kanto T	Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis	Journal of Gastroenterology	56(5):	470-478	2021	○
47) <u>田中純子</u> 、杉山文、栗栖あけみ	てんかんの疫学調査 JMD Cデータの紹介と NDB 活用の必要性	てんかん診療拠点病院運用の手引き		5-8	2021	
48) 永島慎太郎、北原良介、杉山文、沖本真史、E Bunthen、Ouoba Serge、Ko Ko、高蓋寿朗、 <u>田中純子</u>	感染症指定医療機関の医療従事者における mRNA COVID-19 ワクチン接種に伴う SARS-CoV-2 IgG 抗体定量値と中和能との関係	感染症学会雑誌			2021	
49) <u>田中純子</u>	総論：日本におけるウイルス性肝炎の疫学と対策	Medical Science Dijest	47(14)	3-5	2021	○
50) 杉山 文、栗栖あけみ、 <u>田中純子</u>	健診受診者集団における NAFLD の疫学	月刊糖尿病	13(7)	20-25	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
51)	田中純子、秋田智之	C型肝疾患の疫学	消化器内科	3(7)	13-22	2021	○
52)	秋田智之、田中純子	疫学的観点からの COVID-19 流行動態の解析とシミュレーション-広島県データを例として	腎と透析	92(1)	69-79	2021	
53)	Tseng TC, Hosaka T, Liu CJ, Suzuki F, Hong CM, Kumada H, Yang YT, Hsu CY, Su TH, Yang HC, Liu CH, Chen PJ, Chen HH, Kao JH.	Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase.	American Journal of Gastroenterology			in press 2022	○
54)	Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.	Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir	Hepatology Communications	6	36-49	2022	
55)	Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Muraishi N, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Ikeda K, Kumada H.	Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage	Oncology	100	31-38	2022	
56)	Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B	Hepatology Research	52	153-164	2022	
57)	Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H.	Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment	Oncology	99	611-621	2021	
58)	Kasuya K, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kajiwarra A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Eguchi Y, Hashimoto M, Kumada H.	Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib	Internal Medicine	60	345-351	2021	
59)	Suzuki F, Hosaka T, Imaizumi M, Kobayashi M, Ohue C, Suzuki Y, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance	Hepatology Research	51	426-435	2021	
60)	Suzuki F, Sezaki H, Hosaka T, Suzuki Y, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.	Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir	Hepatology Research	51	503-508	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
61)	Fujiyama S, Akuta N, Sezaki H, Kobayashi M, Kawamura Y, <u>Hosaka T</u> , Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study	BMC Gastroenterology	21	189	2021	
62)	Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, <u>Hosaka T</u> , Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H.	Clinicopathological assessment of steatohepatic hepatocellular carcinoma	Clinical Research Hepatology Gastroenterology	6	101799	2021	
63)	Muraishi N, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Iritani S, Fujiyama S, <u>Hosaka T</u> , Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Yasuda I, Kumada H.	Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment	Internal Medicine		PMID: 34511564	2021	
64)	Yamashige D, <u>Hosaka T</u> , Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs	Journal of Gastroenterology	56	1008-1021	2021	
65)	Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.	PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD	BMC Gastroenterology	21	434	2021	
66)	Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, <u>Hosaka T</u> , Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H.	Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment	Oncology	99	169-176	2021	
67)	Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Marino Z, Tateishi R, Minami T, Sangiovanni A, Fornis X, <u>Toyoda H</u> , Brillanti S, Conti F, Degaspero E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Abdelaziz AO, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy CC, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello L, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Camma C, Bruix J, Cabibbo G, Reig M.	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.	Gut			in press	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
68)	Kumada T, Toyoda H , Yasuda S, Miyake N, Tada T, Ito T, Tanaka J	Serial changes in FIB-4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy.	GastroHep			in press	○
69)	Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H , Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH.	Progression rates by age, sex, treatment, and disease activity by AASLD and EASL criteria: data for precision medicine.	Clin Gastroenterol Hepatol			in press	○
70)	Kakegawa T, Sugimoto K, Kuroda H, Suzuki Y, Imajo K, Toyoda H	Diagnostic accuracy of two-dimensional shear wave elastography for liver fibrosis: a multicenter prospective study.	Clin Gastroenterol Hepatol			in press	
71)	Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H , Loomba R, Izumi N	Hepatocellular carcinoma risk assessment for patients with advanced fibrosis after eradication of hepatitis C virus.	Hepatol Commun			in press	○
72)	Imajo K, Toyoda H , Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, Yasui Y, Kurosaki M, Izumi N, Nakajima A, Kumada T	Utility of ultrasound-guided attenuation parameter for the quantification of steatosis with reference to MRI-based proton density fat fraction: a multicenter, prospective study.	Clin Gastroenterol Hepatol			in press	
73)	Kam LY, Huang DQ, Teng MLP, Takahashi H, Tanaka K, Yasuda S, Fung J, Lee TY, Hyogo H, Ono M, Saruwatari J, Oniki K, Yeo YH, Barnett S, Henry L, Li J, Zou B, Cheung RC, Kumada T, Yuen MF, Eguchi Y, Toyoda H , Nguyen MH	Clinical profiles of Asians with NAFLD: a systematic review and meta-analysis.	Dig Dis			in press	
74)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y.	Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.	Eur J Gastroenterol Hepatol			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
75)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M.	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to 7 criteria –multicenter analysis.	Hepatol Res			in press	
76)	Atsukawa M, Tsubota A, Kondo C, <u>Toyoda H</u> , Nakamura M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K, KTK49 Liver Study Group	Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis	Hepatol Res			in press	○
77)	Kawamura N, Imajo K, Kalutkiewicz KJ, Nagai K, Iwaki M, Kobayashi T, Nogami A, Honda Y, Kessoku T, Ogawa Y, Higurashi T, Hosono K, Takahashi H, Yoneda M, Saito S, Aishima S, <u>Toyoda H</u> , Hayashi H, Sumida Y, Ehman RL, Nakajima A.	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology			in press	
78)	Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study	Clin Gastroenterol Hepatol			in press	○
79)	Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, <u>Toyoda H</u> , Ogawa C, Kudo M, JSUM AI investigators.	Development of artificial intelligence (AI) for the ultrasonographic diagnosis of liver tumor and comparison of diagnostic accuracy with AI versus human experts.	J Gastroenterol			in press	
80)	Johnson P, Pinato DJ, Kalyuzhnyy A, <u>Toyoda H</u>	Breaking the Child-Pugh dogma in hepatocellular carcinoma	J Clin Oncol			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
81)	Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kumada T.	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a landmark analysis.	Hepatol Res			in press	
82)	Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, <u>Toyoda H</u> , Esquivel CO, Bonham CA, Nguyen MH, Huang DQ.	Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies	Hepatol Commun			in press	
83)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T, Tanaka J.	Adherence to regular surveillance visits for HCC in patients with chronic hepatitis C virus infection who achieved sustained virologic response.	Eur J Gastroenterol Hepatol			in press	○
84)	<u>Toyoda H</u> , Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, Tanaka J.	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.	Eur Radiol			in press	○
85)	Hiraoka A, Kumada T, Kariyama K, <u>Toyoda H</u> , Yasuda S, Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Ishikawa T, Tada T, Takaguchi K, Itobayashi E, Shimada N, Tanaka T, Tsutsui A, Nagano T, Imai M, Nakamura S, Nouse K, Shibata H.	Simple scoring system for predicting TACE unsuitable among intermediate stage hepatocellular carcinoma patients in multiple systemic treatment era.	Oncology	100	65-73	2022	
86)	Tada T, Kumada T, <u>Toyoda H</u> , Nakamura S, Endo Y, Kaneoka Y, Hiraoka A, Joko K, Hirooka M, Hiasa Y	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma	Clin Radiol	77	114-120	2022	
87)	Kumada T, <u>Toyoda H</u> , Yasuda S, Ito T, Tanaka J.	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	Hepatol Res	52	81-92	2022	○
88)	Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo AA, Sanai FM, Derbala MFM, Ormeci N, Dalekos GN, Al-Busafi SA, Hamoudi W, Sharara AI, Zaky S, El-Raey F, Mabrouk MS, Marzouk SY, <u>Toyoda H</u>	Development and multicenter validation of FIB-6; a novel, machine-learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in CHC patients.	Hepatol Res	52	165-175	2022	○
89)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T.	Long-term persistence of hepatocarcinogenic potential of a non-hypervascular hypointense nodule on EOB-MRI after the eradication of hepatitis C virus.	Hepatol Res	52	128-132	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
90)	Yamamoto T, Ito T, Hase, T, Ishigami, M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, <u>Toyoda H</u> , Abe T, Kawashima H, Hashimoto N, Fujishiro M	Immune-related liver injury is a poor prognostic factor in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.	Cancer Invest	40	189-198	2022	
91)	Tada T, <u>Toyoda H</u> , Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J.	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.	J Viral Hepat	28	538-547	2021	○
92)	Itokawa N, Atsukawa M, Tsubota A, Shimada N, <u>Toyoda H</u> , Takaguchi K, Hiraoka A, Senoh T, Koeda M, Yoshida Y, Okubo T, Arai T, Hayama K, Nakagawa-Iwashita A, Kondo C, Iwakiri K.	Factors associated with hepatitis B surface antigen kinetics and responses in pegylated interferon alpha-2a monotherapy for patients with chronic hepatitis B.	Intern Med	60	507-516	2021	○
93)	Yoshida K, Desbiolles A, Feldman SF, Ahn SH, Alidjinou EK, Atsukawa M, Bocket L, Brunetto MR, Buti M, Carey I, Caviglia GP, Chen EQ, Chuaypen N, Cornberg M, Enomoto M, Honda M, zu Siederdisen CH, Ishigami M, Janssen HLA, Maasoumy B, Matsui T, Matsumoto A, Nishiguchi S, Riveiro-Barciela M, Takaki A, Tangkijvanich P, <u>Toyoda H</u> , van Campenhout MJH, Wang B, Wei L, Yang HI, Yano Y, Yatsushashi H, Yuen MF, Tanaka E, Lemoine M, Tanaka Y, Shimakawa Y.	Assay for hepatitis B core-related antigen identify patients with high viral load: systematic review and meta-analysis of individual participant data.	Clin Gastroenterol Hepatol	19	46-60	2021	○
94)	Saito A, <u>Toyoda H</u> , Kobayashi M, Koiwa Y, Fujii H, Fujita K, Maeda A, Kaneoka Y, Hazama S, Nagano H, Mirza A, Graf HP, Cosatto E, Murakami Y, Kuroda M.	Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning.	Mod Pathol	34	417-425	2021	
95)	Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y.	Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis.	Eur J Gastroenterol Hepatol	32	261-268	2021	
96)	Kumada T, <u>Toyoda H</u> , Tada T, Yasuda S, Miyake N, Tanaka J.	Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.	Eur J Gastroenterol Hepatol	32	255-260	2021	○
97)	Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, Sreedharan A, Ustianowski AA, Agarwal K, Mutimer D, Kumada T, <u>Toyoda H</u> , Irving WL, HCV Research UK.	Impact of direct acting antiviral agents on liver function in patients with chronic hepatitis C virus infection.	J Viral Hepat	28	168-176	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
98)	Hughes DM, Berhane S, de Groot CAE, <u>Toyoda H</u> , Tada T, Kumada T, Satomura S, Nishida N, Kudo M, Kimura T, Osaki Y, Kokamunage-Dona R, Salvador RA, Bird T, Garcia-Finana M, Johnson P.	Serum levels of alpha fetoprotein increased more than 10 years before detection of hepatocellular carcinoma.	Clin Gastroenterol Hepatol	19	162-170	2021	○
99)	Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, <u>Toyoda H</u> .	Outcomes of sequential therapy with tenofovir alafenamide following long-term entecavir.	Am J Gastroenterol	116	1264-1273	2021	○
100)	Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouse K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y	Impact of early lenvatinib administration on survival in patients with intermediate-stage hepatocellular carcinoma: a multicenter, inverse probability weighting analysis	Oncology	99	518-527	2021	
101)	<u>Toyoda H</u> , Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, Liu J, Quek SXZ, Ishikawa T, Arai T, Yokohama K, Chuma M, Takaguchi K, Uojima H, Senoo T, Dang H, Maeda M, Hoang J, Le RH, Yasuda S, Thin KN, Tran S, Chien N, Henry L, Asai A, Fukunishi S, Cheung R, Lim SG, Trinh HN, Nguyen MH.	Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice.	Hepatology	74	656-666	2021	○
102)	<u>Toyoda H</u> , Yasuda S, Shiota S	Editorial: is there a "precursor" HCC lesion and can it be detected by hepatobiliary contrast-enhanced magnetic resonance imaging? - authors' reply.	Aliment Pharmacol Ther	54	204-205	2021	
103)	<u>Toyoda H</u> , Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, Tanaka J.	Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI is a strong predictor of HCC development after SVR in patients with HCV infection.	Aliment Pharmacol Ther	53	1309-1316	2021	○
104)	Chuma M, Uojima H, Hiraoka A, Kobayashi S, <u>Toyoda H</u> , Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouse K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S.	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis.	Hepatol Res	51	201-215	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
105)	Nouso K, Furubayashi Y, Kariyama K, Wakuta A, Miyake N, Inoue K, Nagai Y, Murakami S, Adachi T, Oyama A, Wada N, Takeuchi Y, Sakata M, Yasunaka T, Onishi H, Shiraha H, Takaki A, Shiota S, Yasuda S, <u>Toyoda H</u> , Kawanaka M, Kumada T, Okada H.	Abnormal fucosylation of alpha-fetoprotein in patients with non-alcoholic steatohepatitis.	Hepato Res	51	548-553	2021	
106)	Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, <u>Toyoda H</u> , Ogawa C, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M	Therapeutic efficacy of lenvatinib as third line treatment following regorafenib for unresectable hepatocellular carcinoma progression	Hepato Res	51	880-889	2021	
107)	Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassinetti LG, Nicola S, Piscaglia F, Kumada T, Kim HD, Koga H, Vivaldi C, Solda C, Hiraoka A, Bang Y, Atsukawa M, Torimura T, Tsuji K, Itobayashi E, <u>Toyoda H</u> , Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A.	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis.	Liver Int	41	1389-1397	2021	
108)	Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, Torimura T, Iavarone M, Tortora R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawaka K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A.	Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib	Liver Int	41	2997-3008	2021	
109)	Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, <u>Toyoda H</u> , Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M.	Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting.	J Gastroenterol Hepato Res	36	1812-1819	2021	
110)	<u>Toyoda H</u> , Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J.	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.	Nephrol Dial Transpl	36	1097-1103	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
111)	Kumada T, <u>Toyoda H</u> , Yasuda S, Tada T, Tanaka J	Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication	Eur J Gastroenterol Hepatol	33	e513-e521	2021	○
112)	Kumada T, <u>Toyoda H</u> , Yasuda S, Miyake N, Ito T, Tanaka J.	Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.	J Viral Hepat	28	508-516	2021	○
113)	Kumada T, <u>Toyoda H</u> , Yasuda S, Tada T, Ito T, Tanaka J.	Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis	J Viral Hepat	28	1293-1303	2021	○
114)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T, Tanaka J	Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy.	J Infect Chemother	27	1674-1675	2021	○
115)	Yamada N, Matsushima-Nishiwaki R, Kobayashi K, Takahata S, <u>Toyoda H</u> , Kumada T, Kozawa O.	Cellular function of small heat shock proteins (HSPB) in hepatocellular carcinoma.	Cuur Mol Med	21	872-887	2021	
116)	<u>Toyoda H</u> , Hiraoka A, Olivares J, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, Singal AG.	Outcome of hepatocellular carcinoma detected during surveillance: comparing USA and Japan.	Clin Gastroenterol Hepatol	19	2379-2388	2021	○
117)	Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, <u>Toyoda H</u> , Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K.	A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C	PLoS ONE	16	e0257166	2021	○
118)	Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, <u>Toyoda H</u> , Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH.	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.	Hepatol Int	15	71-81	2021	○
119)	Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, Maeda M, Thin KN, Tanaka K, Takahashi Y, Itoh Y, Oniki K, Seko Y, Saruwatari J, Kawanaka M, Atsukawa M, Hyogo H, Ono M, Ogawa E, Barnett SD, Stave CD, Cheung RC, Fujishiro M, Eguchi Y, <u>Toyoda H</u> , Nguyen MH.	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040.	Hepatol Int	15	366-379	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
120)	Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, <u>Toyoda H</u> , Yasuda S, Nguyen MH, Yu ML	Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.	Hepatol Int	15	946-956	2021	
121)	Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Yasuda S, <u>Toyoda H</u> , Yokota K, Hase T, Maeda O, Kato M, Hashimoto N, Hibi H, Ebata T, Kodera Y, Sone M, Ando Y, Akiyama M, Shimoyama Y, Fujishiro M	Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.	Hepatol Int	15	1278-1287	2021	
122)	Schotten C, Ostertag B, Sowa JP, Manka P, Bechmann LP, Hilgard G, Marquardt C, Wichert M, <u>Toyoda H</u> , Lange CM, Canbay A, Johnson P, Wedemeyer H, Best J	GALAD Score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis B and C patients.	Pharmaceuticals	14	735	2021	
123)	Kumada T, <u>Toyoda H</u> , Yasuda S, Sone Y, Ogawa S, Takeshima K, Tada T, Ito T, Sumida Y, Tanaka J	Prediction of hepatocellular carcinoma by liver stiffness measurements using magnetic resonance elastography after eradicating hepatitis C virus.	Clin Transl Gastroenterol	12	e00337	2021	○
124)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience	Cancer Rep	11	e1464	2021	
125)	Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouse K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y.	Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib: an analysis using time-dependent ROC	Sci Rep	11	14474	2021	
126)	Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, <u>Toyoda H</u> , Aoki T, Tanaka T, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M	Effdicacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study	Sci Rep	11	16663	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
127)	Tada T, Kumada T, Okushin H, Tani J, Takaguchi K, Tsutsui A, <u>Toyoda H</u> , Yasuda S, Dohmen K, Hiraoka A, Michitaka K, Nouse K, Kariyama K, Kim SR, Kim SK, Fujioka S, Mikami S, Watanabe Y, Tamai T, Atsukawa M, Itokawa N, Tanaka H, Tsuji K, Ishikawa T, Imai M, Itobayashi E, Shibata H, Shimada N.	Real-world virological efficacy and safety of ledipasvir and sofosbuvir in patients with chronic hepatitis C virus genotype 2 infection in Japan.	Infect Dis Ther	10	269-280	2021	○
128)	Hiraoka A, Kumada T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, <u>Toyoda H</u> , Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M.	What can be done to solve the unmet clinical need of hepatocellular carcinoma patients following lenvatinib failure?	Liver Cancer	10	115-125	2021	
129)	Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, <u>Toyoda H</u> , Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T.	Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update.	Liver Cancer	10	181-223	2021	
130)	Kumada T, <u>Toyoda H</u> , Yasuda S, Tada T, Tanaka J, Chayama K, Johnson PJ, Irving WL	Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus	Infect Dis Ther	10	1001-1013	2021	○
131)	Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Di Costanzo GG, Marra F, Tamburini E, Forgione A, Foschi FG, Silletta M, Lonardi S, Masi G, Scartozzi M, Nakano M, Shibata H, Kawata K, Pellino A, Vivaldi C, Lai E, Takata A, Tajiri K, <u>Toyoda H</u> , Tortora R, Campani C, Viola MG, Piscaglia F, Conti F, Fulgenzi CAM, Frassinetti GL, Rizzato MD, Salani F, Astaro G, Torimura T, Atsukawa M, Tada T, Burgio V, Rimini M, Cascinu S, Casadei-Gardini A	Identification of Lenvatinib Prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.	ESMO Open	6	100190	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
132)	Rimini M, Kudo M, Tada T, Shimose S, Kang W, Suda G, Jefremow A, Burgio V, Iavarone M, Tortora R, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Kumada T, Iwamoto H, Aoki T, Goh MJ, Sakamoto N, Siebler J, Hiraoka A, Niizeki T, Ueshima K, Sho T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouse K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Cucchetti A, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib	ESMO Open	6	100330	2021	
133)	<u>Toyoda H</u> , Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J.	Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response.	Hepatol Commun	5	1290-1299	2021	○
134)	<u>Toyoda H</u> , Yasuda S, Shiota S, Chatani S, Tsukii R, Kitagawa H, Fukushima T, Urasaki S, Kumada T	Safety, feasibility, and comfort of hepatic angiography and transarterial intervention with radial access for hepatocellular carcinoma.	JGH Open	5	1041-1046	2021	
135)	Munoz-Martinez S, Sapena V, Forner A, Nault JC, Sapisochin G, Rimasa L, Sangro B, Bruix J, Sanduzzi-Zamparelli M, Holowko W, El Kassas M, Mocan T, Bouattour M, Merle P, Hoogwater FJH, Alqahatni SA, Reeves HL, Pinato DJ, Giorgakis E, Meyer T, Villadsen GE, Wege H, Salati M, Minguez B, Di Costanzo GG, Roderburg C, Tacke F, Varela M, Galle PR, Alvares-da-Silva MR, Trojan J, Bridgewater J, Cabibbo G, Toso C, Lachenmayer A, Casadei-Gardini A, <u>Toyoda H</u> , Ludde T, Villani R, Pena AMM, Leal CRG, Ronzoni M, Delgado M, Perello C, Pascual S, Lledo JL, Argemi J, Basu B, da Fonseca L, Acevedo J, Siebenhuener AR, Braconi C, Meyers BM, Granito A, Sala M, Lope CR, Blaise L, Romero-Gomez M, Pinero F, Gomez D, Mello V, Pinheiro Alves RC, Franca A, Branco F, Brandi G, Pereira G, Coll S, Guarino M, Benitez C, Anders MM, Bandi JC, Vergara M, Calvo M, Peck-Radosavljevic M, Garcia-Juarez I, Cardinale V, Lozano M, Gambato M, Okolicsanyi S, Arraez DM, Elvevi A, Munoz AE, Lue A, Iavarone M, Reig M.	Assessment of the impact of COVID-19 pandemic on liver cancer management (CERO-19).	JHEP Rep	3	100260	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
136)	Miyasaka A , Yoshida Y, Murakami A, Hoshino T, Sawara K, Numao H, Takikawa Y.	Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection.	Health Sci Rep.	5	e458	2022	○
137)	Miyasaka A , Sato S, Masuda T, Takikawa Y.	A 55-Year-Old Japanese Man with Multiple Sclerosis Diagnosed with Disseminated Tuberculosis Identified by Liver Function Abnormalities: A Case Report.	Am J Case Rep.	22	e931369	2021	
138)	Miyasaka A , Yoshida Y, Suzuki A, Takikawa Y.	Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response.	Qual Life Res.	30	3501-3509	2021	○
139)	Miyasaka A , Yoshida Y, Suzuki A, Sawara K, Takikawa Y.	A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination.	International Journal of General Medicine.	14	9845-9854	2021	○
140)	Ko K, Akita T, Satake M , Tanaka J.	Epidemiology of viral hepatitis C: Road to elimination in Japan	Glob Health Med	3(5)	262-9	2021	○
141)	Matsuno T, Matsuura H, Fujii S, Tanaka A, Satake M , Kinoshita T, Tomita A, Matsui Y, Sugiura Y, Miura Y.	Prolonged incubation period of hepatitis B in a recipient of a nucleic acid amplification test-negative hepatitis B virus window donation.	Transfusion	61(9)	2782-7	2021	
142)	Sakata H, Matsubayashi K, Iida J, Nakauchi K, Kishimoto S, Sato S, Ikuta K, Satake M , Kino S.	Trends in hepatitis E virus infection: Analyses of the long-term screening of blood donors in Hokkaido, Japan, 2005-2019.	Transfusion	61(12)	3390-401	2021	
143)	Shimakami T , Kaneko S.	Use of information and communication technology in the support of viral hepatitis patients in Japan.	Glob Health Med.	3(5)	314-320	2021	○
144)	Kawaguchi K, Sakai Y, Terashima T, Shimode T, Seki A, Orita N, Takeshita Y, Shimakami T , Takatori H, Arai K, Kitamura K, Yamashita T, Yamashita T, Takamura M, Mizukoshi E, Takamura T, Honda M, Wada T, Kaneko S.	Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease.	Medicine (Baltimore)	100(31)	e26835	2021	
145)	Dultz G, Srikakulam SK, Konetschnik M, Shimakami T , Doncheva NT, Dietz J, Sarrazin C, Biondi RM, Zeuzem S, Tampé R, Kalinina OV, Welsch C.	Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability.	J Biol Chem.	297(3)	101031	2021	
146)	Shirasaki T, Murai K, Honda M, Okada H, Innami Y, Yamada A, Shimakami T , Kawaguchi K, Yamashita T, Sakai Y, Kaneko S.	Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice.	Sci Rep.	11(1)	13021	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
147)	Chen H, Nio K, Yamashita T, Okada H, Li R, Suda T, Li Y, Doan PTB, Seki A, Nakagawa H, Toyama T, Terashima T, Iida N, <u>Shimakami T</u> , Takatori H, Kawaguchi K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S.	BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma.	Mol Oncol.	15(8)	2203-2218	2021	
148)	Yamashita T, Koshikawa N, <u>Shimakami T</u> , Terashima T, Nakagawa M, Nio K, Horii R, Iida N, Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kitao A, Kobayashi S, Takahara S, Imai Y, Yoshimura K, Murayama T, Nakamoto Y, Yoshida E, Yoshimura T, Seiki M, Kaneko S.	Serum Laminin γ 2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma.	Hepatology	74(2)	760-775	2021	○
149)	Ogawa Y, Nakahara T, Ono M, Kawaguchi T, Isoda H, Hiramatsu A, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Yamauchi M, Tsuge M, Munekage K, Ochi T, Hayes CN, Imamura M, Aikata H, Takahashi H, <u>Torimura T</u> , Chayama K	Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease	Journal of Gastroenterology and Hepatology			in press 2021	
150)	Shirono T, Koga H, Niizeki T, Nagamatsu H, Iwamoto H, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Ogo E, <u>Torimura T</u>	Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study	Cancer Reports			in press 2021	
151)	Kamachi N, Nakano M, Okamura S, Niizeki T, Iwamoto H, Shimose S, Shirono T, Noda Y, Kuromatsu R, Koga H, <u>Torimura T</u>	Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound	Cancer Reports			in press 2021	○
152)	Iwamoto H, Itano S, Itano O, Ishii M, Niizeki T, Shirono T, Shimose S, Suzuki H, Kajiwara A, Yamaguchi T, Koga H, <u>Torimura T</u>	Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors	Japanese Journal of Radiology			in press 2021	
153)	Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Kajiwara A, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Koga H, <u>Torimura T</u>	Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival	Oncology	99: 12	756-765	2021	○
154)	Yoshimura T, Mitsuyama K, Sakemi R, Takedatsu H, Yoshioka S, Kuwaki K, Mori A, Fukunaga S, Araki Y, Morita M, Tsuruta K, Yamasaki H, <u>Torimura T</u>	Evaluation of Serum Luecine-rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease	Mediators of Inflammation	8825374:	1-10	2021	
155)	Mori A, Mitsuyama K, Sakemi R, Yoshioka S, Fukunaga S, Kuwaki K, Yamauchi R, Araki T, Yoshimura T, Yamasaki H, Tsuruta K, Morita T, Yamasaki S, Tsuruta O, <u>Torimura T</u>	Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease	The Kurume Medical Journal	66: 4	209-215	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
156)	Yamamura S, Kawaguchi T, Nakano D, Tomiyasu Y, Yoshinaga S, Doi Y, Takahashi H, Anzai K, Eguchi Y, <u>Torimura T</u>	Prevalence and Independent Factors for Fatty Liver and Significant Hepatic Fibrosis Using B-Mode Ultrasound Imaging and Two Dimensional-Shear Wave Elastography in Health Check-up Examinees	The Kurume Medical Journal	66: 4	225-237	2021	
157)	Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Costanzo GGDi, Marra F, Tamburini E, Forgione A, Foschi FG, Silletta M, Lonardi S, Masi G, Scartozzi M, Nakano M, Shibata H, Kawata K, Pellino A, Vivaldi C, Lai E, Takata A, Tajiri K, Toyoda H, Tortora R, Campani C, Viola MG, Piscaglia F, Conti F, Fulgenzi CAM, Frassinetti GL, Rizzato MD, Salani F, Astara G, <u>Torimura T</u> , Atsukawa M, Tada T, Burgio V, Rimini M, Cascinu S, Casadei-Gardini A	Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma	ESMO Open	6: 4	100190	2021	
158)	Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, <u>Torimura T</u> , Kurume Liver Cancer Study Group of Japan	Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma	ESMO Open	6: 1	100020	2021	○
159)	Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shigeo S, Shirono T, Noda Y, Kamachi N, Koga H, <u>Torimura T</u>	Evaluating the effect of intrahepatic lesion status on the prognosis of advanced hepatocellular carcinoma patients with extrahepatic metastasis: A prospective multicenter cohort study	Journal of Translational Science	6 :	1-7	2021	
160)	Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, <u>Torimura T</u> , Yoshizawa K, Takaki A, Kang JH, Suzuki Y, Nakamoto N, Inui A, Tanaka A, Takikawa H	Differences in autoimmune hepatitis based on inflammation localization	Medical Molecular Morphology	54: 1	8-13	2021	
161)	Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, George J, <u>Torimura T</u>	MAFLD Better Predicts the Progression of Atherosclerotic Cardiovascular Risk than NAFLD: Generalized Estimating Equation Approach	Hepatology Research	51; 11	1115-1128	2021	
162)	Hashida R, Matsuse H, Kawaguchi T, Yoshio S, Bekki M, Iwanaga S, Sugimoto T, Hara K, Koya S, Hirota K, Nakano D, Tsutsumi T, Kanto T, <u>Torimura T</u> , Shiba N	Effects of A Low-Intensity Resistance Exercise Program on Serum miR-630, miR-5703, and Fractalkine/CX3CL1 Expressions in Subjects with No Exercise Habits: A Preliminary Study	Hepatology Research	51:7	823-833	2021	
163)	Kawaguchi T, Honda A, Sugiyama Y, Nakano D, Tsutsumi T, Tahara N, <u>Torimura T</u> , Fukumoto Y	Association between the Albumin-Bilirubin (ALBI) Score and Severity of Portoplmonary Hypertension (PoPH): A Data-mining Analysis	Hepatology Research	51: 12	1207-1218	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
164)	Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, <u>Torimura T</u> , Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: a multi-institutional matched case-control study	Hepatology Research	51: 12	1229-1241	2021	
165)	Toshihiro Tanaka, Hideki Iwamoto, Mitsuteru Fujihara, Hideyuki Nishiofuku, Tetsuya Masada, Hiroyuki Suzuki, Hironori Koga, <u>Takuji Torimura</u> , Kimihiko Kichikawa	Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma	CardioVascular and Interventional Radiology	44: 5	766-773	2021	
166)	Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassinetti GL, Nicola S, Piscaglia F, Kumada T, Hyung-Don K, Koga H, Vivaldi C, Soldà C, Hiraoka A, Bang Y, Atsukawa M, <u>Torimura T</u> , Tsuj K, Itobayashi E, Toyoda H, Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A	Lenvatinib versus Sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis	Liver International	41: 6	1389-1397	2021	
167)	Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, <u>Torimura T</u> , Iavarone M, Tortora R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A	Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib	Liver International	41: 12	2997-3008	2021	
168)	Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, <u>Torimura T</u> , Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayash N, Sumida Y, Saito S, Nakajima A	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease	Journal of Gastroenterology and Hepatology	36: 8	2275-2284	2021	
169)	Hashida R, Takano Y, Matsuse H, Kudo M, Bekki M, Omoto M, Nago T, Kawaguchi T, <u>Torimura T</u> , Shiba N.	Electrical Stimulation of the Antagonist Muscle during Cycling Exercise Interval Training Improves Oxygen Uptake and Muscle Strength.	Journal of Strength and Conditioning Research	35: 1	111-117	2021	
170)	<u>Torimura T</u> , Iwamoto H	Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects	Clinical and Molecular Hepatology	27: 2	236-245	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
171)	Fukunaga S, Nakano D, Kawaguchi T, Eslam M, Ouchi A, Nagata T, Kuroki H, Kawata H, Abe H, Nouno R, Kawaguchi K, George J, Mitsuyama K, <u>Torimura T</u>	Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study	International journal of molecular sciences	22: 11	5462	2021	
172)	Araki T, Mitsuyama K, Yamasaki H, Morita M, Tsuruta K, Mori A, Yoshimura T, Fukunaga S, Kuwaki K, Yoshioka S, Takedatsu H, Kakuma T, Akiba J, <u>Torimura T</u>	Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease	Journal of Crohn's and Colitis	15: 9	1517-1527	2021	
173)	Toshihiro Kawaguchi, Tatsuya Ide, Keisuke Amano, Teruko Arinaga-Hino, Reiichiro Kuwahara, Tomoya Sano, Shirachi Miki, Naofumi Ono, <u>Takuji Torimura</u>	Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication	Molecular and Clinical Oncology	15: 4	215	2021	○
174)	Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, Shirono T, Nakano M, Hashida R, Kawaguchi T, Matusue H, Noguchi K, Koga H, <u>Torimura T</u>	Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma	Molecular and Clinical Oncology	14: 4	79	2021	○
175)	Fukahori M, Kato K, Taniguchi H, Ohtomo R, Takahashi N, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Hokamura N, Igaki H, Tachimori Y, Miwa K, <u>Torimura T</u> and Boku N	Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations	Molecular and Clinical Oncology	14 : 2	41	2021	
176)	Suzuki H, Iwamoto H, Nakano M, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Kuromatsu R, Niizeki T, Okamura S, Shimose S, Shirono T, Noda Y, Kamachi N, Yano H, Kawaguchi A, Koga H, <u>Torimura T</u>	Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments	Translational Oncology	14 : 11	101201	2021	
177)	Sano T, Amano K, Ide T, Kawaguchi T, Kuwahara R, Arinaga-Hino T, Koga H, Kuromatsu R, <u>Torimura T</u>	Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alafenamide for chronic hepatitis B	Biomedical Reports	14: 1	12	2021	
178)	Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwaru M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, <u>Torimura T</u>	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma	Cancers	13: 4	646	2021	○
179)	Zaizen Y, Nakano M, Fukumori K, Yano Y, Takaki K, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Kuromatsu R, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, <u>Torimura T</u>	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis	Cancers	13: 21	5282	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
180)	Tsuchihashi J, Koya S, Hirota K, Koga N, Narao H, Tomita M, Kawaguchi T, Hashida R, Nakano D, Tsutsumi T, Yoshio S, Matsuse H, Sanada T, Notsumata K, <u>Torimura T</u>	Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma	Cancers	13: 2	194	2021	
181)	Niizeki T, Iwamoto H, Shirono T, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Hiroyuki S, Sakai M, Kuromatsu R, Koga H and <u>Torimura T</u>	Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion	Cancers	13: 17	4450	2021	○
182)	Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, <u>Torimura T</u> and on behalf of The Kurume Liver Cancer Study Group of Japan	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice	Cancers	13: 11	2786	2021	○
183)	Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, <u>Torimura T</u>	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study	Cancers	13: 1	160	2021	○
184)	Hashida R, Dan Nakano, Sakura Yamamura, Takumi Kawaguchi, Tsubasa Tsutsumi, Hiroo Matsuse, Hirokazu Takahashi, ,Zobair M. Younossi and <u>Takuji Torimura</u>	Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis	Life (Basel)	11 : 8	799	2021	
185)	Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, <u>Torimura T</u> , Anzai K, Eguchi Y, Takahashi H	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees	Diagnostics	11: 1	132	2021	
186)	Fukahori M, Miwa K, Murotani K, Naito Y, Ushijima T, Sakaue T, Tanaka T, Nagasu S, Suga H, Kakuma T, Okabe Y, <u>Torimura T</u>	A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer	Medicine	100: 20	26052	2021	
187)	Shirono T, Niizeki T, Iwamoto H, Shimose S, Suzuki H, Kawaguchi T, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatu R, Koga H, <u>Torimura T</u>	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis	Journal of Clinical Medicine	10: 5	987	2021	
188)	Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, <u>Torimura T</u>	First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study	Cancer Medicine	10: 23	8530-8541	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
189)	Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K , Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y.	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma	Liver Cancer			in press 2022	
190)	Nishina S, Hino K .	CD26/DPP4 as a therapeutic target in nonalcoholic steatohepatitis associated hepatocellular carcinoma	Cancers	14	454	2022	
191)	Hino K , Yanatori I, Hara Y, Nishina S.	Iron and liver cancer: an inseparable connection	FEBS J		doi: 10.1111/febs.16208.	2021	
192)	Nishikawa H, Shiraki M, Hiramatsu N, Hata K, Moriya K, Hino K , Koike K.	Reduced Handgrip Strength Predicts Poorer Survival in Chronic Liver Diseases: A Large Multi-Center Study in Japan	Hepato Res	51	957-967	2021	
193)	Sasaki K, Nishina S, Yamauchi A, Fukuda K, Hara Y, Yamamura M, Egashira K, Hino K .	Nanoparticle-mediated delivery of 2-deoxy-D-glucose induces antitumor immunity and cytotoxicity in liver tumors in mice	Cell Mol Gastroenterol Hepatol	11	739-762	2021	
194)	Nishida N, Sugiyama M, Ohashi J, Kawai Y, Khor SS, Nishina S, Yamasaki K, Yazaki H, Okudera K, Tamori A, Eguchi Y, Sakai A, Kakisaka K, Sawai H, Tsuchiura T, Ishikawa M, Hino K , Sumazaki R, Takikawa Y, Kanda T, Yokosuka O, Yatsuhashi H, Tokunaga K, Mizokami M.	Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines	Sci Rep	11	3703	2021	○
195)	Honma Y, Miyagawa K, Hara Y, Hayashi T, Kusanaga M, Ogino N, Minami S, Oe S, Ikeda M, Hino K , Harada M.	Correlation of hepatitis C virus-mediated endoplasmic reticulum stress with autophagic flux impairment and hepatocarcinogenesis.	Med Mol Morphol	54	108-121	2021	
196)	Nishina S, Tomiyama K, Ikuta Y, Tatsumi Y, Toki A, Kato K, Yoshioka N, Sasaki K, Hara Y, Hino K .	Long-term phlebotomy successfully alleviated hepatic iron accumulation in a ferroportin disease patient with a mutation in SLC40A1: a case report	BMC Gastroenterol	21	111	2021	
197)	Toda M, Yoshifuji A, Kikuchi K , Komatsu M, Fujii K, Kato A, Kikuchi T, Nakazawa A, Ryuzaki M	Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients	Clin Exp Nephrol	8	1-10	2022	
198)	Sugawara Y, Iwagami M, Yoshida Y, Kikuchi K , Ando R, Shinoda T, Ryuzaki M, Nakamoto H, Sakai K, Hanafusa N, Kashiwara N, Nangaku M	Nationwide survey of the coronavirus disease 2019 prevention and treatment systems for kidney disease patients: a study of Japanese Society of Nephrology-certified educational facilities	Clin Exp Nephrol	31	1-7	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
199)	Sugawara Y, Iwagami M, <u>Kikuchi K</u> , Yoshida Y, Ando R, Shinoda T, Ryuzaki M, Nakamoto H, Sakai K, Hanafusa N, Kashihara N, Nangaku M;	Infection prevention measures for patients undergoing hemodialysis during the COVID-19 pandemic in Japan: a nationwide questionnaire survey	Ren Replace Ther	7	27	2021	
200)	Maruyama Y, Kanda E, <u>Kikuchi K</u> , Abe M, Masakane I, Yokoo T, Nitta K	Association between anemia and mortality in hemodialysis patients is modified by the presence of diabetes	J Nephrol.	34	781-790	2021	
201)	Toyoda H, <u>Kikuchi K</u> , Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.	Nephrol Dial Transplant	36	1097-1103.	2021	○
202)	<u>Kikuchi K</u> , Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Nakamoto H, Akizawa T	Survival and Predictive Factors in Dialysis Patients with COVID-19 in Japan: A Nationwide Cohort Stud	Ren Replace Ther	7	59	2021	
203)	Que L, Li Y, Dainichi T, Kukimoto I, Nishiyama T, Nakano Y, Shima K, Suzuki T, Sato Y, Horike S, <u>Aizaki H</u> , Watashi K, Kato T, Aly HH, Watanabe N, Kabashima K, Wakae K, Muramatsu M.	Interferon-gamma induced APOBEC3B contributes to Merkel cell polyomavirus genome mutagenesis in Merkel cell carcinoma.	J Invest Dermatol.	27		2021	
204)	Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshioka K, Tanaka J, Muramatsu M, Wakita T, <u>Aizaki H</u> .	Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers.	Hepato Int.	2	1-13	2021	○
205)	Ishizaka A, Koga M, Mizutani T, Lim LA, Adachi E, Ikeuchi K, Ueda R, Aoyagi H, Tanaka S, Kiyono H, Matano T, <u>Aizaki H</u> , Yoshio S, Mita E, Muramatsu M, Kanto T, Tsutsumi T, Yotsuyanagi H.	Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus.	Viruses.	18		2021	
206)	Fukano K, Oshima M, Tsukuda S, <u>Aizaki H</u> , Ohki M, Park SY, Wakita T, Wakae K, Watashi K, Muramatsu M. NTCP oligomerization occurs downstream of the NTCP-EGFR interaction during hepatitis B virus internalization.	NTCP oligomerization occurs downstream of the NTCP-EGFR interaction during hepatitis B virus internalization.	J Virol.	6		2021	
207)	Yang Z, Ouyang T, Aoyagi H, Wang T, Xing X, Zhang Y, Wang Y, Li Y, <u>Aizaki H</u> [corresponding author], Li S, Kong L.	Cellular OCIAD2 protein is a proviral factor for hepatitis C virus replication.	Int J Biol Macromol.	1;188	147-159	2021	
208)	Zheng X, Guo R, Liu Q, Wakae K, Watanabe N, Fukano K, Que L, Li Y, Aly HH, Watashi K, Suzuki R, Murayama A, Kato T, <u>Aizaki H</u> , Wakita T, Huang X, Yan Y, Song SJ, Muramatsu M.	Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus.	Biochem Biophys Res Commun.	11;567	1-8	2021	
209)	Takeda H, Takai A, Iguchi E, Mishima M, Arasawa S, Kumagai K, Eso Y, Shimizu T, Takahashi K, Ueda Y, Taura K, Hatano E, Iijima H, Aoyagi H, <u>Aizaki H</u> , Marusawa H, Wakita T, Seno H.	Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus.	Carcinogenesis.	22		2021	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
210) Imai K, Takai K, Miwa T, Maeda T, Hanai T, Shiraki M, Suetsugu A, <u>Shimizu M</u> .	Increased visceral adipose tissue and hyperinsulinemia raise the risk for recurrence of Non-B Non-C hepatocellular carcinoma after curative treatment.	Cancers	13	1542	2021	○
211) Hanai T, Shiraki M, Nishimura K, Miwa T, Maeda T, Ogiso Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u> .	Usefulness of the stroop test in diagnosing minimal hepatic encephalopathy and predicting overt hepatic encephalopathy.	Hepato Comm	5	1518-1526	2021	○
212) Hanai T, Hiraoka A, Shiraki M, Sugimoto R, Taniki N, Hiramatsu A, Nakamoto N, Iwasa M, Chayama, <u>Shimizu M</u>	Utility of the SARC-F questionnaire for sarcopenia screening in patients with chronic liver disease: A multicenter cross-sectional study in Japan.	J Clin Med	10	3448	2021	○
213) Hanai T, Nishimura K, Miwa T, Maeda T, Ogiso Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u>	Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.	J Gastroenterol	56	928-937	2021	○
214) Hanai T, Shiraki M, Nishimura K, Ogiso Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u> .	Nutritional assessment tool for predicting sarcopenia in chronic liver disease.	JCSM Rapid Commun	4	150-158	2021	○
215) Miwa T, Hanai T, Toshihide M, Ogiso Y, Imai K, Suetsugu A, Takai K, Shiraki M, Katsumura N, <u>Shimizu M</u> .	Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy.	Hepato Res	51	662-673	2021	○
216) Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, <u>Shimizu M</u> , Tani M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.	J Gastroenterol	56	593-619	2021	○
217) Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, <u>Shimizu M</u> , Tani M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.	Evidence-based clinical practice guidelines for liver cirrhosis 2020.	Hepato Res	51	725-749	2021	○
218) Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, <u>Shimizu M</u> , Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.	J Gastroenterol	56	67-77	2021	○

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
219) Takaoka Y, Miura K, Morimoto N, <u>Ikegami T</u> , Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H, Liver Investigators in the Northern Kanto Study (LINKS) group.	Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.	Hepatol Res.	51(1)	51-61	2021	
220) Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators (<u>Ikegami T</u>)	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.	J Gastroenterol	56(3)	261-273	2021	○
221) 榎本大、日高勲、井上泰輔、磯田広史、井出達也、荒生祥尚、内田義人、井上貴子、 <u>池上正</u> 、柿崎暁、瀬戸山博子、島上哲朗、小川浩司、末次淳、井上淳、遠藤美月、永田賢治、是永匡紹	肝疾患診療連携拠点病院における肝炎医療コーディネーターの現状	肝臓	62(2)	96-98	2021	○

	著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	<u>保坂哲也</u>	B型肝炎の核酸アナログによる治療	茶山一彰	雑誌消化器内科#6	医学出版	東京	2020	90-97	○
2)	<u>保坂哲也</u>	核酸アナログ治療中B型慢性肝疾患での拾い上げ	持田智	雑誌月刊消化器・肝臓内科	科学評論社	東京	2020	382-386	○
3)	<u>保坂哲也</u>	B型肝炎の無症候性キャリアはがんにならない?	加藤直也	消化器診療をスッキリまとめました	南江堂	東京	2020	158-165	○
4)	<u>保坂哲也</u>	B型慢性肝炎	持田智	肝臓専門医テキスト	南江堂	東京	2020	306-310	
5)	<u>保坂哲也</u>	無治療・無症候性および非活動性キャリアの場合	竹原徹郎	困ったウイルス肝炎パーフェクト対応ガイド	南江堂	東京	2020	26-30	○
6)	Kawaguchi T, Yamamura S, Nakano D, Tomiyasu Y, Yoshinaga S, Doi Y, Takahashi H, Anzai K, Eguchi Y, Torimura T	An Association between Mild-to-moderate Drinking and Hepatic Fibrosis Evaluated by Shear Wave Elastography in Health Check-up Examinees	アルコール医学生物学研究会 編	アルコールと医学生物学 Vol. 39	響文社	札幌	2020	p.40-41	
7)	<u>菊地勸</u>	第5章 各種感染症患者に対する感染予防とその治療 I B型肝炎ウイルス(HBV), C型肝炎ウイルス(HCV)	秋葉隆	透析施設における標準的な透析操作と感染予防に関するガイドライン(五訂版)	三秀舎	東京	2020	89-98	○
8)	<u>相崎英樹</u> 、 <u>脇田隆</u> 字、 <u>坂本亭</u> 字	C型肝炎からの発癌機序		肝癌診療マニュアル第4版	医学書院	東京	2020	7-9	
9)	<u>池上正</u>	胆嚢結石症、総胆管結石症(内科)	持田智	今日の治療指針 私はこう治療している Today's therapy 2020	医学書院	東京	2019	567-568	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Kumada T, Toyoda H, Tada T, Yasuda S, Miyake N, Tanaka J	Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels	European journal of gastroenterology and hepatology	32(2)	255-260	2021	○
2)	Honmyo N, Kobayashi T, Kuroda S, Oshita A, Onoe T, Kohashi T, Fukuda S, Ohmori I, Abe T, Imaoka Y, Akita T, Tanaka J , Ohdan H	A novel model for predicting posthepatectomy liver failure based on liver function and degree of liver resection in patients with hepatocellular carcinoma	HPB	23(1)	134	2021	○
3)	Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis	Journal of Viral Hepatitis	28(3)	538-547	2021	○
4)	Nagashima S, Ko K, Yamamoto C, Bunthen E, Ouoba S, Chuon C, Ohisa M, Sugiyama A, Akita T, Hossain MS, Ork V, Mao B, Tanaka J	Prevalence of total hepatitis A antibody among 5 to 7 years old children and their mothers in Cambodia	Scientific Reports	11(1)	4778	2021	○
5)	Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, Tanaka J	Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis	Journal of Viral Hepatitis	28(3)	508-516	2021	○
6)	Razavi H et al. (Tanaka J 含む 193人中163番目)	The case for simplifying and using absolute targets for viral hepatitis elimination goals	Journal of Viral Hepatitis	28(1)	12-19	2021	○
7)	Ko K, Nagashima S, Yamamoto C, Takahashi K, Matsuo J, Ohisa M, Akita T, Matyakubov J, Mirzaev U, Katayama K, Masaki T, Tanaka J	Eighteen-year follow-up cohort study on hepatitis B and C virus infections related long-term prognosis among hemodialysis patients in Hiroshima	Journal of Medical Virology	92	3436-3447	2020	○
8)	Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J , Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M, Liver Cancer Study Group of Japan	Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey	Annals of surgery	272(1)	145-154	2020	○
9)	Tada T, Kumada T, Toyoda H, Yasuda S, Sone Y, Hashinokuchi S, Ogawa S, Oguri T, Kamiyama N, Chuma M, Akita T, Tanaka J	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis	Hepatology Research	50(2)	190-198	2020	○
10)	Lingani M, Akita T, Ouoba S, Nagashima S, Boua PR, Takahashi K, Kam B, Sugiyama A, Nikiema T, Yamamoto C, Some A, Derra K, Ko K, Sorgho H, Tanagda Z, Tinto H, Tanaka J	The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: A multistage stratified random sampling survey	BMC Infectious Disease	20(1)	46	2020	○
11)	Yamamoto C, Nagashima S, Isomura M, Ko K, Chuon C, Akita T, Katayama K, Woodring J, Hossain MS, Takahashi K, Tanaka J	Evaluation of the efficiency of dried blood spot-based measurement of hepatitis B and hepatitis C virus seromarkers	Scientific Reports	10(1)	3857	2020	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Ko K, Takahashi K, Nagashima S, Yamamoto C, Ork V, Sugiyama A, Akita T, Ohisa M, Chuon C, Shafiqul Hossain M, Mao B, <u>Tanaka J</u>	Existence of hepatitis B virus surface protein mutations and other variants: demand for hepatitis B infection control in Cambodia	BMC Infectious Disease	20(1)	305	2020	○
13)	Yamamoto C, Nagashima S, Chuon C, Ko K, Do SH, Lim O, Hok S, Svay S, Matsuo J, Katayama K, Takahashi K, <u>Tanaka J</u>	Substitution of the CD81 binding site and beta-sandwich area in E2 of HCV in Cambodia	viruses	12(5)	551	2020	○
14)	Kumada T, Toyoda H, Yasuda S, Tada T, Ogawa S, Takeshima K, <u>Tanaka J</u> , Chayama K, Johnson PJ	Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study	Alimentary Pharmacology and Therapeutics	52(2)	359-370	2020	○
15)	Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, <u>Tanaka J</u>	Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: an analysis using a Markov chain model	Hepatology Research	50(8)	936-946	2020	○
16)	Kumada T, Toyoda H, Tada T, Yasuda S, <u>Tanaka J</u>	Changes in background liver function in patients with hepatocellular carcinoma over 30 years: Comparison of Child-Pugh classification and albumin bilirubin grade	Liver Cancer	9(5)	518-528	2020	○
17)	Miki D, Akita T, Kurisu A, Kawaoka T, Nakajima T, Hige S, Karino Y, Toyoda H, Kumada T, Tsuge M, Hiramatsu A, Imamura M, Aikata H, Hayes CN, Honda K, Seike M, Akuta N, Kobayashi M, Kumada H, <u>Tanaka J</u> , Chayama K	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication	Journal of Gastroenterology	55(12)	1162-1170	2020	○
18)	<u>田中純子</u> 、秋田智之	疫学：慢性 C 型肝炎	病原微生物検出情報（月報）	42(1)	3-4	2021	○
19)	<u>田中純子</u> 、秋田智之、菊池勘	疫学の視点からみた C 型肝炎	月間薬事	63(4)	20-25	2021	○
20)	<u>田中純子</u>	わが国の B 型肝炎ウイルス感染症の現状と展望	臨床消化器内科	35(2)	127-135	2020	○
21)	<u>田中純子</u> 、秋田智之、山本周子	SDGs 目標のウイルス肝炎排除を目指したアジア地域の共同開発研究：HBV に焦点を当てて	アグリバイオ	4(1)	59-66	2020	○
22)	<u>田中純子</u>	わが国における肝炎ウイルス感染の実態と今後の見通し	消化器内科	2(5)	6-16	2020	○
23)	<u>田中純子</u>	ウイルス肝炎の疫学	日本医師会雑誌	148(11)	2145-2149	2020	○
24)	<u>田中純子</u> 、秋田智之	疫学	消化器外科	43(12)	1629-1638	2020	○
25)	<u>田中純子</u> 、秋田智之、永島慎太郎	SDGs 目標のウイルス肝炎排除を目指したアジア地域の共同開発研究；HBV に焦点を当てて	地域ケアリンク	22(14)	63-70	2020	○
26)	<u>Satake M</u> , Kozakai M, Matsumoto M, Matsubayashi K, Taira R, Goto N.	Platelet safety strategies in Japan: impact of short shelf life on the incidence of septic reactions.	Transfusion.	60(4)	731-738	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
27)	Shinohara N, Owada T, Tanaka A, Matsubayashi K, Nagai T, <u>Satake M.</u>	Hepatitis A virus and hepatitis E virus prevalence relates to human immunodeficiency virus infection in Japanese male blood donors.	Microbiol Immunol.	64(5)	392-395	2020	
28)	Abe H, Endo K, Shiba M, Niibe Y, Miyata S, <u>Satake M.</u>	Flow path system of ultraviolet C irradiation from xenon flash to reduce bacteria survival in platelet products containing a platelet additive solution.	Transfusion.	60(5)	1050-1059	2020	
29)	Ito S, Kaito S, Miyazaki T, Kikuchi G, Isa K, Tsuneyama H, Kurita R, Ogasawara K, Uchikawa M, <u>Satake M.</u>	A new antigen SUMI carried on glycoprotein A encoded by the GYPA*M with c.91A>C (p.Thr31Pro) belongs to the MNS blood group system.	Transfusion.	60(6)	1287-1293	2020	
30)	Kozakai M, Matsumoto C, Matsumoto M, Takakura A, Matsubayashi K, <u>Satake M.</u>	Different growth kinetics in blood components and genetic analysis of Lactococcus garvieae isolated from platelet concentrates.	Transfusion.	60(7)	1592-1499	2020	
31)	Tsuneyama H, Isa K, Watanabe-Okochi N, Ogasawara K, Uchikawa M, <u>Satake M.</u>	An unusual variant glycoprotein expressing protease-resistant M antigen encoded by the GYPB-E(2-4)-B hybrid gene.	Vox Sang	115(7)	579-585	2020	
32)	Akita T, Tanaka J, <u>Satake M.</u> , Lin Y, Wada T, Kato K, Inoue M.	Meta-regression Analysis of Sex- and Birth Year-Specific Prevalence of HBsAg and Anti-HCV Among Un-diagnosed Japanese: Data From the First-time Blood Donors, Periodical Health Checkup, and the Comprehensive Health Checkup With Lifestyle Education (Ningen Dock).	J Epidemiol.	30(9)	420-425	2020	○
33)	Abe H, Endo K, Nogawa M, Shiba M, Miyata S, <u>Satake M.</u>	In vitro thrombus formation and in vivo hemostasis mediated by platelets irradiated with bactericidal ultraviolet C from xenon flash under flow conditions.	Transfusion.	Ahead of print		2020	
34)	Sagara Y, Nakamura H, Yamamoto M, Ezaki T, Koga T, Shimamura M, <u>Satake M.</u> , Irita K.	Estimation of the window period of human T-cell leukemia virus type 1 and 2 tests by a lookback study of seroconverters among Japanese voluntary blood donors.	Transfusion.	Ahead of print		2020	
35)	Yato K, Onodera T, Matsuda M, Moriyama S, Fujimoto A, Watashi K, <u>Aizaki H.</u> Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Tamura K, Takahashi Y, Wakita T, Muramatsu M, Kato T, Suzuki R.	Identification of Two Critical Neutralizing Epitopes in the Receptor Binding Domain of Hepatitis B Virus preS1.	J Virol.	9		2020	
36)	Li Y, Que L, Fukano K, Koura M, Kitamura K, Zheng X, Kato T, Aly HH, Watashi K, Tsukuda S, <u>Aizaki H.</u> Watanabe N, Sato Y, Suzuki T, Suzuki HI, Hosomichi K, Kurachi M, Wakae K, Muramatsu M	MCPIP1 reduces HBV-RNA by targeting its epsilon structure.	Sci Rep.	27		2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
37)	Gewaid H, Aoyagi H, Arita M, Watashi K, Suzuki R, Sakai S, Kumagai K, Yamaji T, Fukasawa M, Kato F, Hishiki T, Mimata A, Sakamaki Y, Ichinose S, Hanada K, Muramatsu M, Wakita T, Aizaki H.	Sphingomyelin Is Essential for the Structure and Function of the Double-Membrane Vesicles in the Viral RNA Replication Factories.	J Virol.	16		2020	
38)	Wakae K, Kondo S, Pham HT, Wakisaka N, Que L, Li Y, Zheng X, Fukano K, Kitamura K, Watashi K, Aizaki H. , Ueno T, Moriyama-Kita M, Ishikawa K, Nakanishi Y, Endo K, Muramatsu M, Yoshizaki T.	EBV-LMP1 induces APOBEC3s and mitochondrial DNA hypermutation in nasopharyngeal cancer.	Cancer			2020	
39)	Fujimi TJ, Mezaki Y, Masaki T, Tajima A, Nakamura M, Yoshikawa A, Murai N, Aizawa M, Kojima S, Matsumoto Y, Aizaki H. , Matsuura T.	Investigation of the effects of urea cycle amino acids on the expression of ALB and CEBPB in the human hepatocellular carcinoma cell line FLC-4.	Hum Cell	33	590-598	2020	
40)	Kong L, Aoyagi H, Yang Z, Ouyang T, Matsuda M, Fujimoto A, Watashi K, Suzuki R, Arita M, Yamagoe S, Dohmae N, Suzuki T, Suzuki T, Muramatsu M, Wakita T, Aizaki H.	Surfeit 4 contributes to the replication of hepatitis C virus using double membrane vesicles.	J Virol.	94		2020	
41)	相崎英樹 、石井孝司	A型肝炎	https://www.premedi.co.jp/お医者さんオンライン/h00448			2021	
42)	相崎英樹 、鈴木亮介、加藤考宣、村松正道	ウイルス肝炎(E型肝炎およびA型肝炎を除く)	病原体マニュアル、国立感染症研究所 https://www.niid.go.jp/niid/images/lab-manual/HepatitisBCD20200908.pdf	1	1-14	2020	
43)	Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K. , Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y.	Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial.	Liver Cancer	8	505-519	2019	
44)	Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y, Tomiyama Y, Kuribayashi F, Torimura T, Hino K.	Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.	Cell Mol Gastroenterol Hepatol	7	115-134	2019	
45)	Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K. , Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y, Taxtics study group.	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.	Gut	69	1492-1501	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
46)	Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M, Matano T, Kato J, Tokunaga S, Sugihara T, Hiramatsu A, Hyogo H, Tobita H, Sato S, Kawanaka M, Hara Y, <u>Hino K</u> , Chayama K, Murawaki Y, Isomoto H.	Serum miR-379 expression is related to the development and progression of hypercholesteremia in non-alcoholic fatty liver disease.	PLoS One	15	e0219412	2020	
47)	Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, <u>Hino K</u> , Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Nakashima D, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J.	A randomized double-blind placebo-controlled phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.	Cancer Sci	111	3759-3769 doi: 10.1111/cas.14582.	2020	
48)	Hara Y, Yanatori I, Tanaka A, Kishi F, Lemasters JJ, Nishina S, Sasaki K, <u>Hino K</u> .	Iron loss triggers mitophagy through induction of mitochondrial ferritin.	EMBO Rep	21,11	e50202.	2020	
49)	Sasaki K, Nishina S, Yamauchi A, Fukuda K, Hara Y, Yamamura M, Egashira K, <u>Hino K</u> .	Nanoparticle-mediated delivery of 2-deoxy-D-glucose induces antitumor immunity and cytotoxicity in liver tumors in mice.	Cell Mol Gastroenterol Hepatol		doi: 10.1016/j.jcmgh.2020.10.010	2020	
50)	<u>Miyasaka A</u> , Kumagai I, Masuda T, Takikawa Y.	A 51-Year-Old Woman with Drug-Induced Hypersensitivity Syndrome Associated with Carbamazepine, Reactivation of Human Herpesvirus 6, and Acute Liver Failure: a case report	American Journal of case reports	22	e928587	2021	
51)	<u>Miyasaka A</u> , Yoshida Y, Suzuki A, Masuda T, Okamoto H, Takikawa Y.	Hepatitis B reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.	Medicine	99	e22650	2020	
52)	Kumagi I, Suzuki K, Kitada K, Kondo K, Kato A, Yoshida Y, <u>Miyasaka A</u> , Takikawa Y, Kaneko Y, Takahashi M, Okamoto H.	A Male Patient with Acute Hepatitis E Showing Asymptomatic and Transient Hyperthyroidism Due To Autoimmune Thyroiditis.	Japanese Journal of Gastroenterology and Hepatology	4	1-6	2020	
53)	Endo K, Sato T, Suzuki A, Yoshida Y, Kakisaka K, <u>Miyasaka A</u> , Takikawa Y.	Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection.	J Gastroenterol Hepatol.	35	1602-1609	2020	
54)	Nishikawa T, Nagata N, <u>Shimakami T</u> , Shirakura T, Matsui C, Ni Y, Zhuge F, Xu L, Chen G, Nagashimada M, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S, Ota T.	Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.	Sci Rep	10(1)	815	2020	
55)	Hashiba T, Yamashita T, Okada H, Nio K, Hayashi T, Asahina Y, Hayashi T, Terashima T, Iida N, Takatori H, <u>Shimakami T</u> , Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Takamura H, Ohta T, Honda M, Kaneko S.	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.	Gastroenterol Hepatol	10(2)	269-285	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
56)	Terashima T, Honda M, Toyama T, <u>Shimakami T</u> , Shimizu R, Takatori H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S.	IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.	J Gastroenterol Hepatol.	35(10)	1813-1820	2020	
57)	Shimizu Y, Arai K, Yamashita T, Yamashita T, <u>Shimakami T</u> , Kawaguchi K, Kitamura K, Sakai Y, Mizukoshi E, Honda M, Kitao A, Kozaka K, Kobayashi S, Kaneko S.	Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver.	Liver Cancer.	9(3)	261-274	2020	
58)	Dultz G, <u>Shimakami T</u> , Schneider M, Murai K, Yamane D, Marion A, Zeitler TM, Stross C, Grimm C, Richter RM, Bäumer K, Yi M, Biondi RM, Zeuzem S, Tampé R, Antes I, Lange CM, Welsch C.	Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.	J Biol Chem.	295(40)	13862-13874	2020	
59)	Kitabayashi J, Shirasaki T, <u>Shimakami T</u> , Nishiyama T, Welsch C, Funaki M, Murai K, Sumiyadorj A, Takatori H, Kitamura K, Kawaguchi K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S.	Upregulation of the Long Non-Coding RNA HULC by Hepatitis C Virus and its Regulation of Viral Replication.	J Infect Dis			2020	
60)	島上哲朗, 金子周一	石川県における肝炎ウイルス検診陽性者に対するフォローアップシステム	IASR	42	6-8	2021	○
61)	Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, <u>Ikegami T</u> , Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T.	Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection	J Gastroenterol Hepatol	35	855-861	2020	○
62)	Honda A, Miyazaki T, Iwamoto J, Hirayama T, Morishita Y, Ueda H, Mizuno S, Sugiyama F, Takahashi S, <u>Ikegami T</u> .	Bile acid metabolism in a novel mouse model with humanized hydrophobic bile acid composition.	J Lipid Res	61	54-69	2020	
63)	Miyazaki T, Sasaki S, Toyoda A, Wei FY, Shirai M, Morishita Y, <u>Ikegami T</u> , Tomizawa K, Honda A.	Impaired bile acid metabolism with defectives of mitochondrial tRNA taurine modification and bile acid taurine conjugation in the taurine depleted cats.	Sci Rep	10	4915	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
64)	Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, <u>Ikegami T</u> , Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld.	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?	Int J Mol Sci	21	4939	2020	
65)	Iwamoto J, Murakami M, Monma T, Ueda H, Tamamushi M, Konishi N, Yara SI, Hirayama T, <u>Ikegami T</u> , Honda A, Mizokami Y	Current states of prevention of drug-induced gastroduodenal ulcer in real clinical practice: a cross-sectional study.	J Clin Biochem Nutr	66	158-162	2020	
66)	Akuta N, Kawamura Y, Fujiyama S, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H	Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease	Intern Med	59(3)	329-38	2020	
67)	Ogasawara N, Saitoh S, Denpou H, Kinowaki K, Akuta N, Suzuki F, Hashimoto M, Fujiyama S, Kawamura Y, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Fujii T, Kumada H	Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver	Intern Med	59(3)	365-72	2020	
68)	Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, <u>Hosaka T</u> , Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H	18 F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib	Liver Cancer	9(1)	84-92	2020	
69)	Akuta N, Kawamura Y, Fujiyama S, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H	SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology	Intern Med	59(16)	1931-1937	2020	
70)	Akuta N, Kawamura Y, Kobayashi M, Arase Y, Saitoh S, Fujiyama S, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H	TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease	Oncology		doi: 10.1159/000510366	2020	
71)	Iritani S, Akuta N, Kawamura Y, Kajiwarra A, Kasuya K, Fujiyama S, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Kobayashi M, Saito S, Suzuki F, Arase Y, Ikeda K, Suzuki Y, Kumada H	Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease	BMC Gastroenterol	20(1)	368	2020	
72)	Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, <u>Hosaka T</u> , Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H	Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis	Liver Cancer	9(3)	275-92	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
73)	Ogasawara N, Saitoh S, Suzuki F, Kinowaki K, Masuda J, Denpou H, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miura Y, Takano T, Kumada H	Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography	Clin J Gastroenterol		doi: 10.1007/s12328-020-01180-x	2020	
74)	Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH.	Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis	Lancet Gastroenterology & Hepatology	12	1039-1052	2020	
75)	Yeo YH, Tseng TC, Hosaka T, Cunningham C, Fung JYY, Ho HJ, Kwak MS, Trinh HN, Ungtrakul T, Yu ML, Kobayashi M, Le AK, Henry L, Li J, Zhang J, Sriprayoon T, Jeong D, Tanwandee T, Gane E, Cheung RC, Wu CY, Lok AS, Lee HS, Suzuki F, Yuen MF, Kao JH, Yang HL, Nguyen MH.	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients	Clinical Translational Gastroenterology	11	e00196	2020	
76)	Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Tominaga L, Kajiwarra A, Kasuya K, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H.	Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma	Liver Cancer	9	756-770	2020	
77)	Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH.	Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis	Lancet Gastroenterology & Hepatology	5	739-752	2020	
78)	Kajiwarra A, Kinowaki K, Akuta N, Kasuya K, Muraishi N, Iritani S, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Suzuki F, Kumada H, Suzuki Y	Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years	Intern Med	59(20)	2511-6	2020	
79)	Sano T, Akuta N, Suzuki Y, Kasuya K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki F, Kobayashi M, Arase Y, Ikeda K, Kumada H	Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment	Intern Med	59(12)	1519-24	2020	
80)	Ogasawara N, Saitoh S, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H	Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C	Hepatology Res	50(4)	426-38	2020	
81)	Ochiai Y, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwarra A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H	Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease	Hepatology Res		doi: 10.1111/hepr.13572	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
82)	Akuta N, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Saitoh S, Arase Y, Ikeda K, Suzuki Y, Kumada H	Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma	J Med Virol		doi: 10.1002/jmv.25724	2020	
83)	Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, <u>Shimizu M</u>	Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment.	Mol Clin Oncol	12	111-116	2020	○
84)	Hanai T, Shiraki M, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u>	Late evening snack with branched-chain amino acids supplementation improves survival in patients with cirrhosis.	J Clin Med	9	1013	2020	
85)	Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, <u>Shimizu M</u>	Rapid depletion of subcutaneous adipose tissue during sorafenib treatment predicts poor survival in patients with hepatocellular carcinoma.	Cancers (Basel)	12	1795	2020	
86)	Takahashi H, Nakahara T, Kogiso T, Imajo K, Kessoku T, Kawaguchi T, Ide T, Kawanaka M, Hyogo H, Fujii H, Ono M, Kamada Y, Sumida Y, Anzai K, <u>Shimizu M</u> , Torimura T, Nakajima A, Tokushige K	Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study.	JGH Open	5	228-234	2020	○
87)	Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, <u>Torimura T</u>	MAFLD identifies patients with significant hepatic fibrosis better than NAFLD	Liver International	40: 12	3018-3030	2020	
88)	Kawaguchi T, Yamamura S, Nakano D, Tomiyasu Y, Yoshinaga S, Doi Y, Takahashi H, Anzai K, Eguchi Y, <u>Torimura T</u>	An Association between Mild-to-moderate Drinking and Hepatic Fibrosis Evaluated by Shear Wave Elastography in Health Check-up Examinees	アルコールと 医学生物学 Vol. 39	39	40-41	2020	
89)	Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Sakai M, Yamaguchi T, Kuromatsu R, Koga H, <u>Torimura T</u>	Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events	Cancers	12	E1010	2020	○
90)	Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, <u>Torimura T</u>	Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study	Cancers	12	E1867,	2020	○
91)	Sakemi R, Mitsuyama K, Morita M, Yoshioka S, Kuwaki K, Tokuyasu H, Fukunaga S, Mori A, Araki T, Yoshimura T, Yamasaki H, Tsuruta K, Morita T, Yamasaki S, Mizoguchi A, Sou S, <u>Torimura T</u>	Altered serum profile of the interleukin-22 system in inflammatory bowel disease	Cytokine	136	155264	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
92)	Kudo M, Ueshima K, Ikeda M, <u>Torimura T</u> , Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial	Gut	69	1492-1501	2020	
93)	Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, <u>Torimura T</u>	Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis	Hepatology Communications	4	1218-1228	2020	○
94)	Yamamura S, Kawaguchi T, Nakano D, Tomiyasu Y, Yoshinaga S, Doi Y, Takahashi H, Anzai K, Eguchi Y, <u>Torimura T</u> , Shiba N	Profiles of advanced hepatic fibrosis evaluated by FIB-4 index and shear wave elastography in health check up examinees	Hepatology Research	50	199-213	2020	
95)	Hirota K, Kawaguchi T, Koya S, Nagamatsu A, Tomita M, Hashida R, Nakano D, Niizeki T, Matsuse H, Shiba N, <u>Torimura T</u>	Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma	Hepatology Research	50	330-341	2020	
96)	Yamasaki H, Mitsuyama K, Yoshioka S, Kuwaki K, Yamauchi R, Fukunaga S, Mori A, Tsuruta O, <u>Torimura T</u>	Leukocyte Apheresis Using a Fiber Filter Suppresses Colonic Injury Through Calcitonin Gene-Related Peptide Induction	Inflammatory bowel diseases	11	709-719	2020	
97)	Narao H, Hirota K, Koya S, Tomita M, Manako Y, Ogawa S, Nakao N, Tsutsumi T, Nakano D, Hashida R, Kawaguchi T, Matsuse H, Nagamatsu H, <u>Torimura T</u>	Effects of In-Hospital Physical Therapy on Activities of Daily Living in Patients with Hepatocellular Carcinoma	Int J Environ Res Public Health	17	E9098	2020	
98)	Nakano D, Kawaguchi T, Tsutsumi T, Yamamura S, Shigeto K, Hashida R, Koga H, <u>Torimura T</u>	Alteration of the serum myostatin level following L-carnitine treatment in patients with chronic liver disease: A pilot study	International Journal of Functional Nutrition	1	1-7	2020	
99)	Masuda A, Nakamura T, Abe M, Iwamoto H, Sakaue T, Tanaka T, Suzuki H, Koga H, <u>Torimura T</u>	Promotion of liver regeneration and antifibrotic effects of the TGFbeta receptor kinase inhibitor galunisertib in CCl4-treated mice	International Journal of Molecular Medicine	46	427-438	2020	
100)	Hirokazu Takahashi, Takashi Nakahara, Tomomi Kogiso, Kento Imajo, Takaomi Kessoku, Takumi Kawaguchi, Tatsuya Ide, Miwa Kawanaka, Hideyuki Hyogo, Hideki Fujii, Masafumi Ono, Yoshihiro Kamada, Yoshio Sumida, Keizo Anzai, Masahito Shimizu, <u>Takuji Torimura</u> , Atsushi Nakajima, Katsutoshi Tokushige, Kazuaki Chayama, Yuichiro Eguchi, Japan Study Group of NAFLD (JSG-NAFLD)	Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study	JGH Open	5	228-234	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
101)	Kawaguchi T, Yoshio S, Sakamoto Y, Hashida R, Koya S, Hirota K, Nakano D, Yamamura S, Niizeki T, Matsuse H, <u>Torimura T</u>	Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma	Journal of Clinical Medicine	9	E936	2020	○
102)	Morita T, Mitsuyama K, Yamasaki H, Mori A, Yoshimura T, Araki T, Morita M, Tsuruta K, Yamasaki S, Kuwaki K, Yoshioka S, Takedatsu H, <u>Torimura T</u>	Gene Expression of Transient Receptor Potential Channels in Peripheral Blood Mononuclear Cells of Inflammatory Bowel Disease Patients	Journal of Clinical Medicine	9	2643	2020	
103)	Atsushi Takahashi, Masanori Abe, Tetsuya Yasunaka, Teruko Arinaga-Hino, Kazumichi Abe, Akinobu Takaki, <u>Takuji Torimura</u> , Mikio Zeniya, Kaname Yoshizawa, Jong-Hon Kang, Yoshiyuki Suzuki, Nobuhiro Nakamoto, Ayano Inui, Atsushi Tanaka, Hajime Takikawa, Hiromasa Ohira	Quality of life among patients with autoimmune hepatitis in remission	Medicine	99	e22764	2020	
104)	Shimose S, Kawaguchi T, Iwamoto H, Tanaka M, Miyazaki K, Ono M, Niizeki T, Shirono T, Okamura S, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, <u>Torimura T</u>	Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study	Nutrients	12	E1076	2020	○
105)	Shigeto K, Kawaguchi T, Koya S, Hirota K, Tanaka T, Nagasu S, Fukahori M, Ushijima T, Matsuse H, Miwa K, Nagafuji K, <u>Torimura T</u>	Profiles Combining Muscle Atrophy and Neutrophil-to-Lymphocyte Ratio Are Associated With Prognosis of Patients With Stage IV Gastric Cancer	Nutrients	12	E1884	2020	
106)	Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Nomiya M, Kuromatsu R, Koga H, <u>Torimura T</u>	Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma	Oncology	18	1-8	2020	○
107)	Hashida R, Kawaguchi T, Koya S, Hirota K, Goshima N, Yoshiyama T, Otsuka T, Bekki M, Iwanaga S, Nakano D, Niizeki T, Matsuse H, Kawaguchi A, Shiba N, <u>Torimura T</u>	Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma	Oncology Letters	19	2355-2367	2020	○
108)	Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M, Koga H, <u>Torimura T</u>	Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma	Oncology Letters	19	2667-2676	2020	○
109)	Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, <u>Torimura T</u>	Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis	Oncology Letters	20	2257-2265	2020	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
110)	Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, <u>Torimura T</u>	Effects of canagliflozin on growth and metabolic reprogramming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)	PLoS One	15	e0232283	2020	○
111)	Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, <u>Torimura T</u> , Yoshizawa K, Takaki A, JKang JH, Suzuki Y, Nakamoto N, Inui A, Tanaka A& Takikawa H	Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan	Scientific Reports	10	14250	2020	
112)	Imai T, Yamasaki H, Mitsuyama K, Yamaga O, Sugihara G, Kaida Y, Shibata R, Hazama T, Yoshioka S, <u>Torimura T</u> , Fukami K, Yamashita N	Single Needle Granulocyte and Monocyte Apheresis for Ulcerative Colitis: A Retrospective Safety Analysis	The Kurume Medical Journal	66	1-17	2020	
113)	Iwanaga S, Hashida R, Takano Y, Bekki M, Nakano D, Omoto M, Nago T, Kawaguchi T, Matsuse H, <u>Torimura T</u> , Shiba N	Hybrid Training System Improves Insulin Resistance in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study	The Tohoku Journal of Experimental Medicine	252	23-32	2020	
114)	Shindo Y, Mitsuyama K, Yamasaki H, Imai T, Yoshioka S, Kuwaki K, Yamauchi R, Yoshimura T, Araki T, Morita M, Tsuruta K, Yamasaki S, Fukami K, <u>Torimura T</u>	Safety and efficacy of single-needle leukocyte apheresis (LCAP) for treatment of ulcerative colitis	Therapeutic Apheresis and Dialysis	24	503-510	2020	
115)	Kawaguchi T, Ikuta K, Tatsumi Y, Toki Y, Hayashi H, Tonan T, Ohtake T, Hoshino S, Naito M, Kato K, Okumura T, <u>Torimura T</u>	Identification of Heterozygous p.Y150C and p.V274M mutations in the HJV gene in a Japanese patient with mild phenotype of Juvenile hemochromatosis: A Case Report	Hepatology Research	50	144-150	2020	
116)	Fukunaga S, Mori A, Ohuchi A, Yoshioka S, Akiba J, Mistuyama K, Tsuruta O, <u>Torimura T</u>	Abdominal pain, diarrhea and bloody stools in a patient treated for renal cell carcinoma with sunitinib	Journal of Gastroenterology and Hepatology	35	10	2020	
117)	Takumi Kawaguchi, Shigeo Shimose, Sakura Yamamura, Dan Nakano, Masatoshi Tanaka, <u>Takuiji Torimura</u>	Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then	Annals of Translational Medicine	8	1045	2020	○
118)	Kawaguchi T, <u>Torimura T</u>	Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?	Journal of gastroenterology	55	363-364	2020	
119)	鈴木浩之、岩本英希、新関敬、下瀬茂男、城野智毅、山口泰三、矢野博久、奥田康司、古賀浩徳、 <u>鳥村拓司</u>	Stage IVA 巨大肝細胞癌に対し血管内治療と分子標的治療を中心とした集学的治療で長期生存が得られている症例	肝臓	61	418-425	2020	
120)	安元真希子、荒木俊博、岡部義信、新関 敬、城野智毅、石田祐介、牛島知之、阪上尊彦、鶴田 修、 <u>鳥村拓司</u>	巨大総胆管結石に併発した膵十二指腸動脈瘤破裂による胆道出血の1救命例	日本消化器病学会雑誌	117	92-98	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
121)	川口 巧、 <u>鳥村拓司</u>	7. NAFLD/NASH, 肝がんの診断と治療—基礎研究から臨床応用へ— 2) 高血圧・脂質異常症合併例の薬物選択肢	Progress in Medicine	40	497-502	2020	
122)	岡部義信、牛島知之、島松裕、平井真吾、寺部寛哉、安元真希子、佐々木優、榊原重成、 <u>鳥村拓司</u>	内視鏡的胆管結石除去術時のトラブルシューティング	肝胆膵	81	228-233	2020	
123)	岡部義信、牛島知之、島松裕、安元真希子、深堀 理、阪上尊彦、平井真吾、寺部寛哉、石田祐介、鶴田 修、 <u>鳥村拓司</u>	緊急内視鏡的胆管ドレナージ術の実際：急性胆管炎・結石嵌頓・胆石性膵炎を中心に	胆と膵	41	167-173	2020	
124)	川口 巧、 <u>鳥村拓司</u>	[私の治療] 肝性脳症	日本医事新報	5016	47	2020	
125)	川口 巧、橋田竜騎、神谷俊次、広田佳介、永松あゆ、中野暖、堤 翼、山村咲良、下瀬茂男、新関 敬、松瀬博夫、 <u>鳥村拓司</u>	特集：肝硬変診療の新時代 3：肝硬変合併症の診断と治療 (4) 肝硬変におけるサルコペニアとその対策	臨床消化器内科	35	1564-1573	2020	
126)	永田 務、鶴田 修、荒木俊博、南 真平、長 知徳、重藤宏太、草場喜雄、中根智幸、大内彬弘、国武泰史、久永 宏、福永秀平、向笠道太、河野弘志、光山慶一、 <u>鳥村拓司</u>	大腸鋸歯状病変に対する臨床診断の現状と課題：経過観察、選択的治療の観点から	胃と腸	55	1589-1596	2020	
127)	Tanaka Y, Ogawa E, Huang CF, <u>Toyoda H</u> , Jun DW, Tseng CH, Hsu YC, Enomoto M, Takahashi H, Furusyo N, Yeh ML, Iio E, Yasuda S, Lam CPM, Lee DH, Haga H, Yoon E, Ahn SB, Wong G, Nakamura M, Nomura H, Tsai PC, Jung JH, Song DS, Dang H, Maeda M, Henry L, Cheung R, Yuen MF, Ueno Y, Eguchi Y, Tamori A, Yu ML, Hayashi J, Nguyen MH.	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort.	Hepato Int	14	1023-1033	2020	○
128)	Miki D, Akita T, Kurisu A, Kawaoka T, Nakajima T, Hige S, Karino Y, <u>Toyoda H</u> , Kumada T, Tsuge M, Hiramatsu A, Imamura M, Aikata H, Hayes CN, Honda K, Seike M, Akuta N, Kobayashi M, Kumada H, Tanaka J, Chayama K.	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.	J Gastroenterol	55	1162-1170	2020	○
129)	<u>Toyoda H</u> , Tada T, Yasuda S, Mizuno K, Ito T, Kumada T.	Dynamic evaluation of liver fibrosis to assess the risk of hepatocellular carcinoma in patients with chronic hepatitis C who achieved sustained virologic response.	Clin Infect Dis	70	1208-1214	2020	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
130)	Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, <u>Toyoda H</u> , Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, Nuguyen MH.	Effects of cirrhosis and diagnosis scenario in metabolic-associated fatty liver disease-related hepatocellular carcinoma.	Hepatology Commun	5	122-132	2020	
131)	Atsukawa M, Tsubota A, Takaguchi K, <u>Toyoda H</u> , Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K.	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.	J Gastroenterol Hepatol	35	1229-1237	2020	
132)	Tada T, Kumada T, <u>Toyoda H</u> , Nakamura S, Shibata Y, Yasuda S, Watanuki Y, Tsuji K, Fukuda N, Fujioka M, Takeshima K, Niwa F, Ogawa S, Hashinokuchi S, Kataoka S, Ichikawa H, Iijima H.	Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: a comparison with magnetic resonance imaging-determined proton density fat fraction.	Hepatology Res	50	1319-1327	2020	
133)	Fan R, Papatheodoridis G, Sun J, Innes H, <u>Toyoda H</u> , Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen HLA, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J.	aMAP risk score predicts hepatocellular carcinoma development in chronic hepatitis patients: an international cohort collaboration.	J Hepatology	73	1368-1378	2020	
134)	<u>Toyoda H</u> , Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T.	Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic HCV infection in a real-world setting: a large, multicenter study from Japan.	J Gastroenterol Hepatol	35	1420-1425	2020	○
135)	Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, <u>Toyoda H</u> , Wong VWS, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN.	Association between fibrosis stage and outcomes of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.	Gastroenterology	158	1611-1625	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
136)	Huang DQ, Yeo YH, Tan E, Takahashi H, Yasuda S, Saruwatari J, Tanaka K, Oniki K, Kam LY, Muthiah MD, Hyogo H, Ono M, Barnett SD, Li J, Zou B, Fung J, Lee TY, Wong VWS, Yuen MF, Dan YY, Lim SG, Cheung R, <u>Toyoda H</u> , Eguchi Y, Nguyen MH.	ALT levels for Asian with metabolic diseases: a meta-analysis of 86 studies with individual patient data validation.	Hepatology Commun	4	1624-1636	2020	
137)	<u>Toyoda H</u> , Yasuda S, Kumada T.	Editorial: the emergence of nonhypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C - authors' reply.	Aliment Pharmacol Ther	51	169-170	2020	○
138)	<u>Toyoda H</u> , Huang DQ, Le MH, Nguyen MH.	Liver care and surveillance: the global impact of COVID-19 pandemic.	Hepatology Commun	4	1751-1757	2020	
139)	Ito T, Ishigami M, Morooka H, Yamamoto K, Imai N, Ishizu Y, Honda T, Nishimura D, Tada T, Yasuda S, <u>Toyoda H</u> , Kumada T, Fujishiro M.	The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC.	Sci Rep	10	17812	2020	
140)	Tada T, Kumada T, <u>Toyoda H</u> , Yasuda S, Sone Y, Hashinokuchi S, Ogawa S, Oguri T, Kamiyama N, Chuma M, Akita T, Tanaka J.	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis.	Hepatology Res	50	190-198	2020	
141)	Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, <u>Toyoda H</u> , Nguyen MH.	Cure with interferon free DAA is associated with increased survival in patients with HCV related HCC from both East and West.	Hepatology	71	1910-1922	2020	○
142)	Han G, Berhane S, <u>Toyoda H</u> , Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, Garcia-Finana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ	Prediction of survival among patients receiving transarterial chemoembolization: a response-based approach.	Hepatology	72	198-212	2020	
143)	Umezumi T, Tsuneyama K, Kanekura K, Hayakawa M, Tanahashi T, Kawano M, Taguchi Y, <u>Toyoda H</u> , Tamori A, Kuroda M, Murakami Y.	Comprehensive analysis of liver and blood miRNA in precancerous conditions.	Sci Rep	10	21766	2020	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
144) Nozaki A, Atsukawa M, Kondo C, <u>Toyoda H</u> , Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akabane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S.	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.	Hepato Int	14	225-238	2020	
145) Hsu YC, Wong GLH, Chen CH, Peng CY, Yeh ML, Cheung KS, <u>Toyoda H</u> , Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH.	Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B.	Am J Gastroenterol	115	271-280	2020	○
146) Ogawa E, <u>Toyoda H</u> , Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jun MJ, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH for the REAL-C Investigators.	HCV cure rates are reduced in patients with active but not inactive hepatocellular carcinoma- a practice implication.	Clin Infect Dis	71	2840-2848	2020	
147) Hiraoka A, Kumada T, Tada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, <u>Toyoda H</u> , Ohama H, Tsutsui A, Itokawa N, Hayama K, Arai T, Imai M, Nakamura S, Michitaka K, Hiasa Y, Kudo M.	Nutritional index as prognostic indicator in patients receiving lenvatinib treatment for unresectable hepatocellular carcinoma.	Oncology	98	295-302	2020	
148) Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, <u>Toyoda H</u> , Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T.	Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.	Cancer Sci	111	334-342	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
149)	Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Nozaki A, Uojima H, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Nakagawa-Iwashita A, Kondo C, Tada T, <u>Toyoda H</u> , Kumada T, Iwakiri K.	Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B.	JGH Open	5	34-40	2020	○
150)	Kumada T, <u>Toyoda H</u> , Yasuda S, Tada T, Ogawa S, Takeshima K, Tanaka J, Chayama K, Johnson PJ.	Impact of the introduction of direct-acting antiviral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study.	Aliment Pharmacol Ther	52	359-370	2020	○
151)	Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Ie A, Henry L, <u>Toyoda H</u> , Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH.	REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy.	J Infect Dis	221	389-399	2020	○
152)	Kariyama K, Nouse K, Wakuta A, Oonishi A, <u>Toyoda H</u> , Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kumada T	Treatment of intermediate-stage hepatocellular carcinoma in Japan: position of curative therapies.	Liver Cancer	9	41-49	2020	
153)	Sumida Y, Yoneda M, <u>Toyoda H</u> , Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A.	Common drug pipelines for the treatment of diabetic nephropathy and hepatopathy: can we kill two birds with one stone?	Int J Mol Sci	21	4939	2020	
154)	Kumada T, <u>Toyoda H</u> , Tada T, Yasuda S, Tanaka J.	Changes in background liver function in patients with hepatocellular carcinoma over 30 years –comparison of Child-Pugh classification and albumin bilirubin grade–.	Liver Cancer	9	518-528	2020	
155)	Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, <u>Toyoda H</u> , Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A.	Surveillance of hepatocellular carcinoma in nonalcoholic fatty liver disease.	Diagnostics	10	579	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
156)	Mizuno K, Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Kawashima H, Inukai Y, <u>Toyoda H</u> , Yokota K, Hase T, Maeda O, Kiyoi H, Nagino M, Hibi H, Kodera Y, Fujimoto Y, Sone M, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Fujishiro M.	Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.	J Gastroenterol	55	653-661	2020	
157)	Cucchetti A, Zhong J, Berhane S, <u>Toyoda H</u> , Shi KQ, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Ercolani G, Mazzaferro V, Kudo M, Cescon M, Pinna AD, Kumada T, Johnson PJ.	The chances of hepatic resection curing hepatocellular carcinoma.	J Hepatol	72	711-717	2020	
158)	Best J, Bechmann LP, Sowa JP, Sydor S, Dechene A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schutte K, Weiss KH, <u>Toyoda H</u> , Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson PJ, Canbay A.	GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.	Clin Gastroenterol Hepatol	18	728-735	2020	
159)	Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tsutsui A, Shibata H, Tada T, <u>Toyoda H</u> , Nouse K, Itokawa N, Joko K, Hiasa Y, Michitaka K, Imai M, Atsukawa M, Hayama K, Nagano T, Koizumi Y, Fukunishi S, Yokohama K, Kudo M, Arai T.	Post-progression treatment eligibility of unresectable hepatocellular carcinoma patients treated with lenvatinib.	Liver Cancer	9	73-83	2020	
160)	Kariyama K, Nouse K, Hiraoka A, Wakuta A, Oonishi A, Kuzuya T, <u>Toyoda H</u> , Tada T, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kudo M, Kumada T.	EZ (Easy)-ALBI score for predicting hepatocellular carcinoma prognosis.	Liver Cancer	9	734-743	2020	
161)	Chan SDH, <u>Toyoda H</u> , Sanjeeviraman J, Soupe A, Iwamoto M, Wu W, Eto D, Tada T, Kumada T, Zhang JP.	Fully automated rapid quantification of hepatitis C virus RNA in human plasma and serum by integrated on-chip RT-qPCR and capillary electrophoresis.	Sci Rep	10	7379	2020	
162)	Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, <u>Toyoda H</u> , Kumada T, Fujishiro M.	Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease.	Eur J Gastroenterol Hepatol	32	748-753	2020	
163)	Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, <u>Toyoda H</u> , Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y.	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching.	Hepatol Res	50	75-83	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
164)	Atsukawa M, Tsubota A, Kondo C, <u>Toyoda H</u> , Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asai A, Asano T, Ogawa C, Abe H, Hotta N, Shima T, Iio E, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Hidaka I, Moriya A, Tsuji K, Akahane T, Yamashita N, Okubo T, Arai T, Morita K, Kawata K, Tanaka Y, Okanoue T, Maeda S, Kumada T, Iwakiri K.	Real-world clinical application of 12-week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study.	Infect Dis Ther	9	851-866	2020	○
165)	<u>Toyoda H</u> , Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T.	Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C.	J Gastroenterol Hepatol	35	855-861	2020	
166)	Nouso K, Furubayashi Y, Shiota S, Miyake N, Oonishi A, Wakuta A, Kariyama K, Hiraoka A, Tsuji K, Itobayashi E, Shimada N, Ishikawa T, Tachi Y, Tada T, <u>Toyoda H</u> , Kumada T.	Early detection of hepatocellular carcinoma in patients with diabetes mellitus.	Eur J Gastroenterol Hepatol	32	877-881	2020	
167)	Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, <u>Toyoda H</u> , Kumada T, Fujishiro M.	Serum nutritional markers as prognostic factor for hepatic and extrahepatic carcinogenesis in Japanese patients with nonalcoholic fatty liver disease.	Nutr Cancer	72	884-891	2020	
168)	Liang LY, Wong VWS, <u>Toyoda H</u> , Tse YK, Yip TCF, Yuen BWY, Tada T, Kumada T, Lee HW, Lui GCY, Chan HLY, Wong GLH.	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.	J Gastroenterol	55	899-908	2020	○
169)	Tada T, <u>Toyoda H</u> , Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J.	Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: an analysis using a Markov chain model.	Hepatol Res	50	936-946	2020	○
170)	Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y.	Neutrophil-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.	Liver Int	40	968-976	2020	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
171)	Chuma M, Uojima H, Numata K, Hidaka H, <u>Toyoda H</u> , Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S.	Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma.	Cancers (Basel)	26	E293	2020	
172)	Hiraoka A, Kumada T, Tada T, Ogawa C, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, <u>Toyoda H</u> , Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Michitaka K, Hiasa Y, Kudo M.	Therapeutic efficacy of ramucirumab after lenvatinib for postprogression treatment of unresectable hepatocellular carcinoma.	Gastroenterol Rep		goaa042	2020	
173)	Kanda E, Epureanu BI, Adachi T, Tsuruta Y, <u>Kikuchi K</u> , Kashiwara N, Abe M, Masakane I, Nitta K	Application of explainable ensemble artificial intelligence model to categorization of hemodialysis-patient and treatment using nationwide-real-world data in Japan	PLoS One	15	e0233491	2020	
174)	<u>Kikuchi K</u> , Nangaku M, Ryuzaki M, Yamakawa T, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Nakamoto H, Akizawa T	COVID-19 in Dialysis Patients in Japan: Current Status and Guidance on Preventive Measures.	Ther Apher Dial.	24	361-365	2020	
175)	<u>Kikuchi K</u> , Hamano T, Wada A, Nakai S, Masakane I	Predilution Online Hemodiafiltration Is Associated With Improved Survival Compared With Hemodialysis	Kidney Int	95	929-938	2019	
176)	Kanda E, Tsuruta Y, <u>Kikuchi K</u> , Masakane I	Use of vasopressor for dialysis-related hypotension is a risk factor for death in hemodialysis patients: Nationwide cohort study	Sci Rep	9	3362	2019	
177)	Ihara H, <u>Kikuchi K</u> , Taniguchi H, Fujita S, Tsuruta Y, Kato M, Mitsuishi Y, Tajima K, Kodama Y, Takahashi F, Takahashi K, Azuma N.	Use of vasopressor for dialysis-related hypotension is a risk factor for death in hemodialysis patients: Nationwide cohort study	Vaccine	37	6447-6453	2019	
178)	Wakasugi M, Kazama JJ, <u>Kikuchi K</u> , Yasuda K, Wada A, Hamano T, Masakane I, Narita I.	Hemodialysis Product and Hip Fracture in Hemodialysis Patients: A Nationwide Cohort Study in Japan	Ther Apher Dial.	23	507-517	2019	

令和元(2019)年度 研究成果の刊行に関する一覧表 【書籍】

	著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	Kawaguchi T, Nakano D, <u>Torimura T</u>	Chapter 7 Diabetes in Liver Disease	Hitoshi Yoshiji, Kosuke Kaji	Alcoholic/Non-Alcoholic Digestive Diseases	Springer Singapore	Singapore	2019	65-86	
2)	芥田憲夫 熊田博光	肝疾患治療薬－B型・C型肝炎における抗ウイルス療法・抗炎症療法	高久史磨	治療薬ハンドブック 2019	じほう	東京	2019	582-587	
3)	宮坂昭生,黒田英克,及川隆喜,柿坂啓介,吉田雄一,遠藤啓,鈴木悠地,佐藤寛毅,阿部珠美,藤原裕大,岡本卓也,米澤美希,滝川康裕.	当科における肝硬変の成因別実態	西口修平	肝硬変の成因別実態 2018	医学図書出版	東京	2019	36-37	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J	Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model	Journal of Medical Virology	91(10)	1837-1844	2019	○
2)	Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J	The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma	Journal of Gastroenterology	54(9)	829-836	2019	○
3)	Toyoda H, Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J , Kumada T	The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C	Alimentary Pharmacology and Therapeutics	50(11-12)	1232	2019	○
4)	Tanaka J , Akita T, Ko K, Miura Y, Satake M; Epidemiological research group on Viral hepatitis and it's long term course, MHLW	Countermeasures against viral hepatitis B and C in Japan: From an epidemiological point of view	Hepatology Research	49(9)	990-1002	2019	○
5)	Honmyo N, Kobayashi T, Hamaoka M, Kohashi T, Abe T, Oishi K, Tazawa H, Imaoka Y, Akita T, Tanaka J , Ohdan H, Hiroshima Surgical study group of Clinical Oncology (HiSCO)	Comparison of new prognostic systems for patients with resectable hepatocellular carcinoma: Albumin-Bilirubin grade and Albumin-Indocyanine Green Evaluation grade	Hepatology Research	49(10)	1218-1226	2019	○
6)	Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Akita T, Tanaka J , Johnson PJ	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study	Liver International	39(3)	448-454	2019	○
7)	Ork V, Woodring J, Shafiqul Hossain M, Wasley A, Nagashima S, Yamamoto C, Chuon C, Sugiyama A, Ohisa M, Akita T, Ko K, Mao B, Tanaka J	Hepatitis B surface antigen seroprevalence among pre- and post-vaccine cohorts in Cambodia, 2017	Vaccine	37(35)	5059-5066	2019	○
8)	Nagashima S, Yamamoto C, Ko K, Chuon C, Sugiyama A, Ohisa M, Akita T, Katayama K, Yoshihara M, Tanaka J	Acquisition rate of antibody to hepatitis B surface antigen among medical and dental students in Japan after three-dose hepatitis B vaccination	Vaccine	37(1)	145-151	2019	○
9)	Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic	Journal of Gastroenterology and Hepatology	34(6)	1066-1073	2019	○
10)	Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, Tanaka J	Type 2 diabetes mellitus is a risk factor for progression of liver fibrosis in middle-aged patients with nonalcoholic fatty liver disease	Journal of Gastroenterology and Hepatology	34(11)	2011-2018	2019	○
11)	Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J	Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model	European Journal of Gastroenterology and Hepatology	31(11)	1452-1459	2019	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, <u>Tanaka J</u> , Chayama K	Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis	Hepatology Communications	22(3)	348-355	2019	○
13)	Chuon C, Takahashi K, Matsuo J, Katayama K, Yamamoto C, Ko K, Hok S, Nagashima S, Akbar SMF, <u>Tanaka J</u>	High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank.	Scientific Reports	9(1)	12186	2019	○
14)	Shimagaki T, Yoshio S, Kawai H, Sakamoto Y, Doi H, Matsuda M, Mori T, Osawa Y, Fukai M, Yoshida T, Ma Y, Akita T, <u>Tanaka J</u> , Taketomi A, Hanayama R, Yoshizumi T, Mori M, Kanto T	Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma	Scientific Reports	9(1)	15788	2019	○
15)	Yamamoto C, Ko K, Nagashima S, Harakawa T, Fujii T, Ohisa M, Katayama K, Takahashi K, Okamoto H, <u>Tanaka J</u>	Very low prevalence of anti-HAV in Japan: high potential for future outbreak	Scientific Reports	9(1)	1493	2019	○
16)	Sato T, Takemura A, Ikeyama Y, Sakamaki Y, Mimata A, Aoyagi H, <u>Aizaki H</u> , Sekine S, Ito K	Transmission electron microscopy of the benzobromarone-induced change in mitochondrial morphology in HepG2 cells.	Fundam. Toxicol. Sci.	6(8)	281-286.	2019	
17)	Watanabe N, Suzuki T, Date T, Hussan HA, Hmwe SS, <u>Aizaki H</u> , Sugiyama M, Mizokami M, Delaney Iv W, Cheng G, Muramatsu M, Wakita T.	Establishment of infectious genotype 4 cell culture-derived hepatitis C virus.	J Gen Virol.		doi: 10.1099/jgv.0.001378.	2019	
18)	Iwamoto M, Saso W, Nishioka K, Ohashi H, Sugiyama R, Ryo A, Ohki M, Yun JH, Park SY, Ohshima T, Suzuki R, Aizaki H, Muramatsu M, Matano T, Iwami S, Sureau C, Wakita T, Watashi K.	The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network.	J Biol Chem.		doi: 10.1074/jbc.AC119.010366.	2019	
19)	Nakajima S, Watashi K, Fukano K, Tsukuda S, Wakae K, <u>Aizaki H</u> , Muramatsu M, Wakita T, Toyoda T.	Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.	J Gastroenterol.		doi: 10.1007/s00535-019-01643-0.	2019	
20)	Hatanaka T, Naganuma A, Tateyama Y, Yoshinari F, Hoshino T, Sato K, Hmwe SS, <u>Aizaki H</u> , Wakita T, Kakizaki S, Uraoka T.	Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Mono-infection Associated with a High Risk of Acute Liver Failure: A Case Report.	Intern Med.		doi: 10.2169/internalmedicine.2982-19.	2019	
21)	Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, <u>Aizaki H</u> , Ryo A, Yun JH, Park SY, Ohtani N, Muramatsu M, Iwami S, Tanaka Y, Sureau C, Wakita T, Watashi K.	Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization.	Proc Natl Acad Sci U S A.		doi: 10.1073/pnas.1811064116.	2019	
22)	Suzuki R, Matsuda M, Shimoike T, Watashi K, <u>Aizaki H</u> , Kato T, Suzuki T, Muramatsu M, Wakita T.	Activation of protein kinase R by hepatitis C virus RNA-dependent RNA polymerase.	Virology.	529	226-233.	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
23)	Bang BR, Li M, Tsai KN, Aoyagi H, Lee SA, Machida K, <u>Aizaki H</u> , Jung JU, Ou JJ, Saito T.	Regulation of Hepatitis C Virus Infection by Cellular Retinoic Acid Binding Proteins through the Modulation of Lipid Droplet Abundance.	J Virol.		doi: 10.1128/JVI.02302-18.	2019	
24)	Fukano K, Tsukuda S, Oshima M, Suzuki R, <u>Aizaki H</u> , Ohki M, Park SY, Muramatsu M, Wakita T, Sureau C, Ogasawara Y, Watashi K.	Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes.	Front Microbiol.		doi:10.3389/fmicb.	2019	
25)	<u>Akuta N</u> , Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.	Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD	Hepatology Commun	4(1)	66-76	2019	
26)	<u>Akuta N</u> , Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.	Hepatology Res	49(5)	531-539	2019	
27)	<u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-action antivirals regimens.	J Med Virol	91(1)	102-106	2019	
28)	<u>Akuta N</u> , Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance	J Clin Microbiol	57(1)	1-11	2019	
29)	Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, <u>Akuta N</u> , Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.	Aliment Pharmacol Ther	49(4)	457-471	2019	
30)	Kawamura Y, Ikeda K, Shindoh J, Kobayashi Y, Kasuya K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Hashimoto M, Kumada H	No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.	Hepatology Res	49(2)	164-176	2019	
31)	Ogasawara N, Saitoh S, <u>Akuta N</u> , Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Long-term outcome of HCC occurrence, esophageal varices exacerbation and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy.	Hepatology Res	49(12)	1441-1450	2019	
32)	Ogasawara N, Saitoh S, <u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C	Hepatology Res		PMID:31785120	2019	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
33)	Ogasawara N,Saitoh S,Denpou H,Kinowaki K, <u>Akuta N</u> ,Suzuki F,Hashimoto M,Fujiyama S,Kawamura Y,Sezaki H,Hosaka T,Kobayashi M,Suzuki Y,Arase Y,Ikeda K,Fujii T,Kumada H.	Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient With an Otherwise Normal Liver	Intern Med		PMID31619599	2019	
34)	Ohya K,Saitoh S,Fujiyama S,Kawamura Y,Sezaki H,Hosaka T, <u>Akuta N</u> ,Kobayashi M,Kobayashi M,Suzuki F,Suzuki Y,Arase Y,Ikeda K,Kinowaki K,Fujii T,Kondo F,Kumada H.	Primary liver carcinoma with sarcomatous changes:Analysis of 10 cases.	Hepatol Res	49(6)	711-717	2019	
35)	Sano T, <u>Akuta N</u> ,Suzuki F,Kasuya K,Fujiyama S,Kawamura Y,Sezaki H,Hosaka T,Saitoh S,Kobayashi M,Suzuki F,Kobayashi M,Arase Y,Ikeda K,Kumada H.	Role of NS5A-L31/Y93 double wild type in failure of glecaprevir/pibrentasvir double therapy in two patients with history of direct-acting antiviral agents failure:Ultra-deep sequencing analysis	Intern Med	58(18)	2657-2662	2019	
36)	Sezaki H,Suzuki F,Hosaka T,Fujiyama S,Kawamura Y, <u>Akuta N</u> ,Kobayashi M,Suzuki Y,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Kumada H.	Initial-and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections	J Gastroenterol	54(10)	916-927	2019	
37)	Shindoh J,Kawamura Y,Kobayashi Y, <u>Akuta N</u> ,Kobayashi M,Suzuki Y,Ikeda K,Hashimoto M.	Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes After Resection of Hepatocellular Carcinoma	J Gastrointest Surg		PMID:31190124	2019	
38)	Shindoh J,Kawamura Y,Kobayashi Y,Kiya Y,Sugawara T, <u>Akuta N</u> ,Kobayashi M,Suzuki Y,Ikeda K,Hashimoto M.	Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients With Hepatocellular Carcinoma	J Gastrointest Surg	23(1)	76-83	2019	
39)	Suzuki F,Hosaka T,Suzuki Y,Sezaki H, <u>Akuta N</u> ,Fujiyama S,Kawamura Y,Kobayashi M,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Mineta R,Suzuki Y,Kumada H	Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.	J Gastroenterol	54(2)	182-193	2019	
40)	Suzuki H,Kawamura Y,Kinowaki K, <u>Akuta N</u> ,Kasuya K,Fujiyama S,Sezaki H,Hosaka T,Saitoh S,Kobayashi M,Kobayashi M,Arase Y,Ikeda K,Suzuki F,Suzuki Y,Kumada H.	The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies.	Intern Med	58(13)	1891-1895	2019	
41)	Suzuki H,Sezaki H,Suzuki F,Kasuya K,Sano T,Fujiyama S,Kawamura Y,Hosaka T, <u>Akuta N</u> ,Saitoh S,Kobayashi M,Arase Y,Ikeda K,Suzuki Y,Kumada H.	Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy.	Hepatol Res	49(12)	1406-1413	2019	
42)	Takeuchi Y, <u>Akuta N</u> ,Sezaki H,Suzuki F,Fujiyama S,Kawamura Y,Hosaka T,Kobayashi M,Kobayashi M,Saitoh S,Suzuki Y,Arase Y,Ikeda K,Kumada H	Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.	Hepatol Res	49(3)	256-263	2019	
43)	Tanaka T, Miwa K, Fukahori M, Yomoda T, Sakaue T, Nagasu S, Ushijima T, Koga H, <u>Torimura T</u>	A Case of Chemotherapy-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Colon Cancer.	Gan to Kagaku Ryoho. Cancer & Chemotherapy	46 巻, 2 号	259-262	2019	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
44)	Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, Nakamuta M, Oeda S, Eguchi Y, Shakado S, Sakisaka S, Yoshimaru Y, Sasaki Y, Honma Y, Harada M, Seike M, Maeshiro T, Miura S, Nakao K, Mawatari S, Ido A, Nagata K, Matsumoto S, Takami Y, Sohda T, Kakuma T, <u>Torimura T</u>	Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study	Hepatology International	13 巻, 3 号	293-301	2019	○
45)	Yoshitake M, Fukunaga S, <u>Torimura T</u>	Abdominal pain and prolonged fever of unknown cause in a 14-year-old boy	Gastroenterology	156 巻, 6 号	e1-e3	2019	
46)	Yamasaki H, Kinugasa T, Iwasaki S, Yoshioka S, Mizuochi T, Ishibashi M, Nagatsuka K, Yamauchi R, Ishibashi N, Araki T, Mori A, Akagi Y, Mitsuyama K, <u>Torimura T</u>	Questionnaire Survey from the 1st Kurume University Inflammatory Bowel Disease Center Educational Lecture	The Kurume Medical Journal	65 巻, 3 号	109-112	2019	
47)	Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, Wada F, Masuda A, Tanaka T, Fukahori M, Ushijima T, Mihara Y, Naitou Y, Okabe Y, Kakuma T, Ohta K, Nakamura K, <u>Torimura T</u>	Glycosylation of ascites-derived exosomal CD133 is a potential prognostic biomarker in patients with advanced pancreatic cancer	Medical Molecular Morphology	52 巻, 4 号	198-208	2019	
48)	Kawaguchi T, Nakano D, Koga H, <u>Torimura T</u>	Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model	Liver Cancer	8:05	359-372	2019	
49)	Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, <u>Torimura T</u> , Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K	A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update	Journal of Gastroenterology	54:04:00	367-376	2019	
50)	Noda Y, Kawaguchi T, Korenaga M, Yoshio S, Komukai S, Nakano M, Niizeki T, Koga H, Kawaguchi A, Kanto T, <u>Torimura T</u>	High Serum Interleukin-34 Level is a Predictor of Poor Prognosis in Patients with Non-viral Hepatocellular Carcinoma	Hepatology Research	49:09:00	1046-1053	2019	
51)	Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Kawaguchi A, Koga H, Yokokura Y, <u>Torimura T</u>	Prognostic Impact of Transcatheter Arterial Chemoembolization (TACE) Combined with Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma: A Comparison to TACE Alone using Decision-tree Analysis after Propensity Score Matching	Hepatology Research	49:08:00	919-928	2019	
52)	Nagamatsu A, Kawaguchi T, Hirota K, Koya S, Tomita M, Hashida R, Kita Y, Narao H, Manako Y, Tanaka D, Koga N, Nakano D, Niizeki T, Matsuse H, <u>Torimura T</u> , Shiba N	Slow Walking Speed Overlapped with Low Hand Grip Strength in Chronic Liver Disease Patients with Hepatocellular Carcinoma	Hepatology Research	49:12:00	1427-1440	2019	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
53) Kodama K, Kawaguchi T, Hyogo H, Nakajima T, Ono M, Seike M, Takahashi H, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Seko Y, Takehara T, Itoh Y, Nakajima A, Masaki N, <u>Torimura T</u> , Saibara T, Karino Y, Chayama K, Tokushige K	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis	Journal of Gastroenterology and Hepatology	34:09:00	1626-1632	2019	
54) Kawaguchi T, Ide T, Kondo R, Nomura Y, Arinaga-Hino T, Kuwahara R, Amano K, Sano T, Akiba J, Ohshima K, Yano H, <u>Torimura T</u>	Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy	Experimental and Therapeutic Medicine	18; 5	3991-4001	2019	○
55) Noda Y, Kawaguchi T, Kuromatsu R, Komukai S, Nakano M, Niizeki T, Koga H, Kawaguchi A, <u>Torimura T</u>	Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis	Oncology Letters	18:01	227-236	2019	
56) Oeda S, Takahashi H, Isoda H, Komukai S, Imajo K, Yoneda M, Ono M, Hyogo H, Kawaguchi T, Fujii H, Kawanaka M, Sumida Y, Tanaka S, Kawamoto H, <u>Torimura T</u> , Saibara T, Kawaguchi A, Nakajima A, Eguchi Y	Infection phase is a predictor of pruritus in patients with hepatitis B virus infection	Biomedical Reports	11:02	63-69	2019	
57) 安元真希子、荒木俊博、岡部義信、新関 敬、城野智毅、石田祐介、牛島知之、阪上尊彦、鶴田 修、 <u>鳥村拓司</u>	巨大総胆管結石に併発した膵十二指腸動脈瘤破裂による胆道出血の1救命例	日本消化器病学会雑誌	117 巻, 1 号	92-98	2019	
58) 永松あゆ、川口 巧、神谷俊次、広田桂介、中野 暖、橋田竜騎、松瀬博夫、多賀百香、居石哲治、志波直人、 <u>鳥村拓司</u> 、八木 実	肝臓病と栄養療法	Journal of Clinical Rehabilitation	28 巻, 1 号	70-75	2019	
59) 広田桂介、川口 巧、橋田竜騎、永松あゆ、神谷俊次、中野暖、松瀬博夫、志波直人、 <u>鳥村拓司</u>	【特集：肝疾患におけるサルコペニア】サルコペニア治療とマネジメント	消化器・肝臓内科	5 巻, 1 号	103-110	2019	
60) 永田 務、鶴田 修、草場喜雄、森田 拓、中根智幸、大内彬弘、徳安秀紀、福永秀平、火野坂淳、向笠道太、江森啓悟、上野恵里奈、河野弘志、光山慶一、 <u>鳥村拓司</u>	大腸 NBI 拡大観察の基本と最新知見	胃と腸	54 巻, 1 号	9-16	2019	
61) 川口 巧、中野 暖、 <u>鳥村拓司</u>	肝性脳症の発症機序と誘発因子—最近の考え方—	肝胆膵	78 巻, 3 号	355-360	2019	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
62) 大内彬弘、鶴田 修、荒木俊博、長 知徳、草場喜雄、中根智幸、徳安秀紀、永田 務、福永秀平、火野坂淳、向笠道太、江森啓悟、上野恵里奈、河野弘志、光山慶一、 <u>鳥村拓司</u>	PG type と NPG type 隆起型早期大腸癌における生物学的悪性度の相違	胃と腸	54 巻, 6 号	889-896	2019	
63) 神谷俊次、川口 巧、橋田竜騎、志波直人、 <u>鳥村拓司</u>	サルコペニアは脂肪肝でも重要	内科	123 巻, 5 号	1147-1149	2019	
64) 岡部義信、牛島知之、安元真希子、石田祐介、阪上尊彦、深堀理、島松 裕、寺部寛哉、鶴田修、 <u>鳥村拓司</u>	悪性胆道狭窄ステントのステント機能不全に対する内視鏡的対処法	消化器内視鏡	31 巻, 5 号	806-811	2019	
65) 河野弘志、鶴田 修、上野恵里奈、菅原脩平、後藤諒介、深水航、柴田 翔、渡邊裕次郎、山田康正、伊藤陽平、小林起秋、光山慶一、 <u>鳥村拓司</u>	主題：隆起型早期大腸癌の病態と診断 PG type 隆起型早期大腸癌の内視鏡診断 通常内視鏡観察の立場から	胃と腸	54 巻, 2 号	847-858	2019	
66) 川口 巧、 <u>鳥村拓司</u>	脂肪肝・NASH の人種差とやせ型 NASH	Medical Practice	36 巻, 9 号	1395-1399	2019	
67) 川口 巧、角田圭雄、 <u>鳥村拓司</u>	NAFLD/NASH の薬物療法の現状と展望	Pharma Medica	37 巻, 19 号	55-59	2019	
68) 岡部義信、牛島知之、安元真希子、石田祐介、阪上尊彦、深堀理、島松 裕、寺部寛哉、鶴田修、 <u>鳥村拓司</u>	胆管結石除去時のトラブルシューティング-結石除去の工夫とバスケット嵌頓時の対応について-	消化器内視鏡	31 巻, 11 号	1677-1683	2019	
69) 中野 暖、山村咲良、川口巧、 <u>鳥村拓司</u>	基礎疾患を有する NAFLD/NASH の治療	消化器の臨床	22 巻, 4 号	303-308	2019	
70) 田中俊光、三輪啓介、深堀理、四方田隆任、阪上尊彦、長主祥子、牛島知之、古賀浩徳、 <u>鳥村拓司</u>	Modified FOLFOX6+Panitumumab 療法中に高アンモニア血症による意識障害を発症した切除不能進行大腸癌の 1 例	癌と化学療法	46;2	259-262	2019	
71) Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y, Tomiyama Y, Kuribayashi F, Torimura T, <u>Hino K.</u>	Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice.	Cell Mol Gastroenterol Hepatol	7	115-134	2019	
72) <u>Hino K.</u> , Nishina S, Sasaki K, Hara Y.	Mitochondrial damage and iron metabolic dysregulation in hepatitis C virus infection.	Free Radic Biol Med	133	193-199	2019	
73) Harigae H, <u>Hino K.</u> , Toyokuni S.	Iron soul of life on earth revised: From chemical reaction, ferroptosis to therapeutics.	Free Radic Biol Med	133	1-2	2019	
74) Nishida N, Sugiyama M, Sawai H, Nishina S, Sakai A, Ohashi J, Khor SS, Kakisaka K, Tsuchiya T, <u>Hino K.</u> , Sumazaki R, Takikawa Y, Murata K, Kanda T, Yokosuka O, Tokunaga K, Mizokami.	Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to hepatitis B vaccine.	Hepatology	68	848-858	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
75)	Miyasaka A, Yoshida Y, Suzuki A, Ueda H, Morino Y, Takikawa Y.	A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection.	Clin J Gastroenterol.	13(1)	90-96	2020	○
76)	Miyasaka A, Yoshida Y, Wang T, Takikawa Y.	Next-generation sequencing analysis of the human T-cell and B-cell receptor repertoire diversity before and after hepatitis B vaccination.	Hum Vaccin Immunother.	15(11)	2738-2753	2019	
77)	Kakisaka K, Sakai A, Yoshida Y, Miyasaka A, Takahashi F, Sumazaki R, Takikawa Y.	Hepatitis B Surface Antibody Titers at One and Two Years after Hepatitis B Virus Vaccination in Healthy Young Japanese Adults.	Intern Med.	58(16)	2349-2355	2019	
78)	Yoshida Y, Yonezawa M, Okamoto T, Fujiwara Y, Suzuki A, Suzuki Y, Endo K, Kakisaka K, Oikawa T, Kuoda H, Miyasaka A, Takikawa Y.	Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.	Clin J Gastroenterol.	12	120-127	2019	○
79)	Tanaka J, Akita T, Ko K, Miura Y, Satake M; Epidemiological Research Group on Viral Hepatitis and its Long-term Course, Ministry of Health, Labour and Welfare of Japan.	Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view.	Hepatol Res	49(9)	990-1002	2019	○
80)	Hoshi Y, Hasegawa T, Yamagishi N, Mizokami M, Sugiyama M, Matsubayashi K, Uchida S, Nagai T, Satake M.	Optimal titer of anti-HBs in blood components derived from donors with anti-HBc.	Transfusion	59(8)	Nov-02	2019	
81)	Murai K, Honda M, Shirasaki T, Shimakami T, Omura H, Misu H, Kita Y, Takeshita Y, Ishii KA, Takamura T, Urabe T, Shimizu R, Okada H, Yamashita T, Sakai Y, Kaneko S.	Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity.	Cell Host Microbe.	25(4)	588-601	2019	
82)	Doncheva NT, Domingues FS, McGivern DR, Shimakami T, Zeuzem S, Lengauer T, Lange CM, Albrecht M, Welsch C.	Near-Neighbor Interactions in the NS3-4A Protease	J Mol Biol.	431(12)	2354-2368	2019	
83)	Omura H, Liu F, Shimakami T, Murai K, Shirasaki T, Kitabayashi J, Funaki M, Nishikawa T, Nakai R, Sumiyadorj A, Hayashi T, Yamashita T, Honda M, Kaneko S.	Establishment and Characterization of a New Cell Line Permissive for Hepatitis C Virus Infection.	Sci Rep.	9(1)	7943-	2019	
84)	Horii R, Honda M, Shirasaki T, Shimakami T, Shimizu R, Yamanaka S, Murai K, Kawaguchi K, Arai K, Yamashita T, Sakai Y, Yamashita T, Okada H, Nakamura M, Mizukoshi E, Kaneko S.	MicroRNA-10a Impairs Liver Metabolism in Hepatitis C Virus-Related Cirrhosis Through Deregulation of the Circadian Clock Gene Brain and Muscle Aryl Hydrocarbon Receptor Nuclear Translocator-Like 1.	Hepatol Commun.	3(12)	1687-1703.	2019	
85)	Miyazaki T, Sasaki S, Toyoda A, Shirai M, Ikegami T, Matsuzaki Y, Honda A	Influences of taurine deficiency on bile acids of the bile in the cat model	Adv Exp Med Biol.	1155	35-44	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
86)	Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, <u>Ikegami T</u> , Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K	"The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.	Aliment Pharmacol Ther.	49(9)	1230-1241	2019	○
87)	Itokawa N, Atsukawa M, Tsubota A, <u>Ikegami T</u> , Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study	Hepatol Res.	49(2)	125-135	2019	
88)	Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, <u>Ikeda H</u> , Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan	Hepatol Res.	49(4)	369-376	2019	○
89)	Miyazaki T, Honda A, <u>Ikegami T</u> , Iida T, Matsuzaki Y	Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model	J Clin Biochem Nutr	64(2)	112-123	2019	
90)	Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, <u>Ikegami T</u> , Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T	Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan	Journal of Viral Hepatitis	26(11)	1266-1275	2019	○
91)	Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, <u>Ikegami T</u> , Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T	Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan	Open Forum Infect Dis.	6(5)	6:ofz185	2019	○
92)	Yara S, <u>Ikegami T</u> , Miyazaki T, Murakami M, Iwamoto J, Hirayama T, Kohjima M, Nakamuta M, Honda A	Circulating bile acid profiles in Japanese patients with NASH	GastroHep	1(6)	302-310	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
93)	上田元, 岩本淳一, 林明慶, 門馬匡邦, 村上昌, 玉虫惇, 小西直樹, 屋良昭一郎, 平山剛, 本多彰, 池上正	出血性消化管病変を呈したAnaphylactoid 紫斑病の一例	Progress of Digestive Endoscopy	94(1)	78-80	2019	
94)	池上正, 屋良昭一郎, 村上昌, 岩本淳一, 宮崎照雄, 本多彰	消化器生活習慣病における酸化ステロールの意義. 特集: 胆汁酸とアンチエイジング	日本抗加齢学会雑誌	15(2)	180-186	2019	
95)	岩本淳一, 門馬匡邦, 上田元, 村上昌, 宮崎照雄, 池上正, 本多彰, 松崎靖司	胆汁酸と消化吸収	消化器・肝臓内科	5(5)	498-504	2019	
96)	Tada T, <u>Toyoda H</u> , Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J	Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos (t)ide analogue therapy: an analysis using a Markov chain model	Eur J Gastroenterol Hepatol	31(11)	1452-1459	2019	○
97)	Mizuno K, <u>Toyoda H</u> , Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J	The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma	J Gastroenterol	54(9)	829-836	2019	○
98)	Ikeda H, Watanabe T, Atsukawa M, <u>Toyoda H</u> , Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T, the KTK49 Liver Study Group	Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve non-cirrhotic genotype 1 and 2 HCV patients in a real-world setting in Japan	J Viral Hepat	26(11)	1266-1275	2019	○
99)	Tada T, <u>Toyoda H</u> , Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J.	Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model	J Med Virol	91(10)	1837-1844	2019	○
100)	<u>Toyoda H</u> , Yasuda S, Kumada T	Editorial: the emergence of nonhypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C - authors' reply	Aliment Pharmacol Ther	51	169-170	2020	○
101)	Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, <u>Toyoda H</u> , Nouse K, Joko K, Hiasa Y, Michitaka K, Kudo M.	Validation of modified ALBI grade for more detailed assessing hepatic function of hepatocellular carcinoma - multicenter analysis.	Liver Cancer	8	121-129	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
102)	Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouse K, <u>Toyoda H</u> , Tada T, Ochi M, Murakami T, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yomago H, Iwasaki R, Tomida H, Miyamoto Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Michitaka K	Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis	J Gastroenterol Hepatol	34	436-441	2019	
103)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: a post-hoc analysis of a multicenter study	J Gastroenterol Hepatol	34	364-369	2019	○
104)	Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Nishimura D, <u>Toyoda H</u> , Kumada T, Goto H, Hirooka Y	Utility and limitations of non-invasive fibrosis markers for predicting prognosis in biopsy-proven Japanese NAFLD patients	J Gastroenterol Hepatol	34	207-214	2019	
105)	Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, Hirooka M, Tsutsui A, Shibata H, Tada T, <u>Toyoda H</u> , Nouse K, Joko K, Hiasa Y, Michitaka K	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis	Hepatol Res	49	111-117	2019	
106)	Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Nakagawa-Iwashita A, Kondo C, Mikami S, Asano T, Matsuzaki Y, <u>Toyoda H</u> , Kumada T, Iio E, Tanaka Y, Iwakiri K.	Efficacy of direct-acting antivirals treatment in patients with compensated liver cirrhosis: a multicenter study	Hepatol Res	49	125-135	2019	○
107)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K, Sone Y, Akita Y, Tanaka J, Johnson PJ	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: a prospective observational study	Liver Int	39	448-454	2019	○
108)	<u>Toyoda H</u>	Direct-acting antiviral therapy for chronic HCV genotype 4 infection: exploring new regimens	Health Sci Rep	2	e106	2019	○
109)	Tada T, Kumada T, <u>Toyoda H</u> , Kobayashi N, Sone Y, Oguri T, Kamiyama N	Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: comparison with MRI-determined proton density fat fraction	Am J Roentogenol	212	332-341	2019	
110)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Nakamura M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan	Hepatol Res	49	369-376	2019	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
111)	Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Ochi H, Tada T, <u>Toyoda H</u> , Nouse K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions – multicenter analysis	Cancer Med	8	137-146	2019	
112)	Tada T, Kumada T, <u>Toyoda H</u> , Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic	J Gastroenterol Hepatol	34	1066-1073	2019	
113)	Nakashima M, <u>Toyoda H</u> , Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T	Influence of renal dysfunction on dose reduction and virological efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection	Hepatol Res	49	512-520	2019	○
114)	Kariyama K, Nouse K, <u>Toyoda H</u> , Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M	Utility of FIB-4-T as a prognostic factor for hepatocellular carcinoma	Cancers (Basel)	11	E203	2019	
115)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Nakamura M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K	The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study	Aliment Pharmacol Ther	49	1230-1241	2019	○
116)	Amoros R, King R, <u>Toyoda H</u> , Kumada T, Johnson PJ, Bird TG	A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma	METRON	77	67-86	2019	
117)	Tada T, Kumada T, <u>Toyoda H</u> , Yasuda S, Koyabu T, Nakashima M	Impact of branched-chain amino acid granule therapy in patients with hepatocellular carcinoma who have normal albumin levels and low branched-chain amino acid to tyrosine ratios	Nutr Cancer	6	1-10	2019	
118)	Nakamura S, Nouse K, Okada H, Onishi H, Fujioka S, Araki Y, Iwadou S, Kumada T, <u>Toyoda H</u> , Motomura K, Kariyama K, Kobashi H, Kaneyoshi T, Ando M, Moriya A, Taniguchi H, Morimoto Y, Hagihara H, Tanaka M	Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment	Hepatoma Res	5	16	2019	○
119)	<u>Toyoda H</u> , Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J, Kumada T	The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C	Aliment Pharmacol Ther	50	1232-1238	2019	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
120)	Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, <u>Shimizu M.</u>	Rapid depletions of subcutaneous fat mass and skeletal muscle mass predict worse survival in patients with hepatocellular carcinoma treated with sorafenib.	Cancers (Basel)	11	1206	2019	
121)	Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, <u>Shimizu M.</u>	Homeostatic model assessment of insulin resistance for predicting the recurrence of hepatocellular carcinoma after curative treatment.	Int J Mol Sci	20	E605	2019	
122)	Hanai T, Shiraki M, Miwa T, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, <u>Shimizu M.</u>	Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis.	Hepatol Res	49	82-95	2019	
123)	Hanai T, Shiraki M, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, <u>Shimizu M.</u>	Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score-matching analysis.	J Gastroenterol Hepatol	34	1809-1816	2019	